{"gene":"AREG","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1988,"finding":"Amphiregulin (AREG) was purified to homogeneity from conditioned medium of PMA-treated MCF-7 human breast carcinoma cells as a bifunctional glycoprotein that inhibits growth of certain human carcinoma cells while stimulating proliferation of human fibroblasts and other tumor cells; biological activity requires intact disulfide bonds.","method":"Protein purification (heparin affinity, HPLC, gel permeation), SDS-PAGE, bioassays, chemical modification","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — original purification to homogeneity with functional characterization using multiple orthogonal methods","pmids":["3413110"],"is_preprint":false},{"year":1989,"finding":"Amphiregulin is a 78–84 amino acid protein whose C-terminal half (residues 46–84) is homologous to the EGF family, while the N-terminal half is unusually hydrophilic and heparin-binding; it binds the EGF receptor but with lower affinity than EGF and fully substitutes for EGF in murine keratinocyte growth.","method":"Protein sequencing, receptor binding competition assay, keratinocyte growth assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — complete amino acid sequence determination with receptor binding and functional assays; foundational structure-function study","pmids":["2466334"],"is_preprint":false},{"year":1990,"finding":"The AREG gene encodes a 252-amino-acid transmembrane precursor (similar to TGF-α precursor organization) from which the mature 84-aa protein is derived; AREG gene was localized to chromosomal region 4q13–4q21; AREG exhibits tumor-inhibitory activity on aggressive carcinoma lines while promoting normal epithelial cell growth.","method":"Gene cloning and sequencing, Northern blot, chromosomal mapping, cell growth assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — gene structure determination with functional characterization, replicated by multiple labs","pmids":["2325643"],"is_preprint":false},{"year":1990,"finding":"Schwannoma-derived growth factor (SDGF) is identical to amphiregulin and functions as an autocrine mitogen for Schwann cells and a mitogen for astrocytes and fibroblasts, demonstrating AREG's role in the nervous system.","method":"Protein purification, sequence determination, mitogenesis assays on glial cells and fibroblasts","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — purification and sequencing confirming identity; functional assays across multiple cell types","pmids":["2234093"],"is_preprint":false},{"year":1991,"finding":"Keratinocyte autocrine factor (KAF) is identical to amphiregulin; heparin sulfate inhibits AREG mitogenic activity by blocking its ability to compete with EGF for cell surface binding, establishing a negative regulatory mechanism for AREG signaling.","method":"Protein purification, N-terminal microsequencing, ELISA, competitive binding assay, cell proliferation assay with heparin sulfate","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — identity confirmed by sequencing and ELISA; heparin inhibition mechanism directly demonstrated","pmids":["2017164"],"is_preprint":false},{"year":1992,"finding":"CRDGF (colorectum cell-derived growth factor) produced by HT29 colon cancer cells is identical to amphiregulin; AREG stimulates phosphorylation of the EGF receptor on tyrosine residues, indicating the AR intracellular signaling pathway involves activation of EGF-R kinase.","method":"Protein purification, N-terminal sequencing, Western blot with AR-specific antiserum, EGF receptor phosphorylation assay","journal":"Growth factors","confidence":"High","confidence_rationale":"Tier 1 — direct EGF-R tyrosine phosphorylation demonstrated by biochemical assay; identity confirmed by sequencing and immunoblot","pmids":["1333777"],"is_preprint":false},{"year":1995,"finding":"Areg and Btc (betacellulin) are tightly linked on mouse chromosome 5; a previously described growth factor SDGF is confirmed as a species variant of Areg, clarifying the evolutionary relationships within the EGF ligand family.","method":"Interspecific backcross mapping, genomic analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic mapping; confirms SDGF/AREG identity through genomic evidence","pmids":["7590736"],"is_preprint":false},{"year":1996,"finding":"AREG, like EGF, TGF-α, and HB-EGF, couples primarily through EGFR (ErbB1) to drive tyrosine phosphorylation and physiological proliferative responses; these ligands do not directly activate ErbB-2 (Neu) alone but require EGFR as an intermediary, distinguishing them functionally from neuregulins which directly bind ErbB-3/4.","method":"Ba/F3 cell lines expressing single and pairwise ErbB receptors, receptor tyrosine phosphorylation assays, IL-3-independent survival/proliferation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted receptor-specific signaling using defined cell panels with rigorous comparison across all four ErbB family members","pmids":["8702723"],"is_preprint":false},{"year":1997,"finding":"Transgenic overexpression of human AREG driven by the keratin-14 promoter in basal keratinocytes induces a psoriasis-like skin phenotype with hyperkeratosis, acanthosis, and inflammatory infiltration, establishing that aberrant AREG expression is sufficient to drive psoriatic-like pathology in vivo.","method":"Transgenic mouse model (K14-ARGE), histological analysis, phenotypic characterization","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — in vivo gain-of-function with defined cellular phenotype; links AREG expression directly to skin pathology","pmids":["9410906"],"is_preprint":false},{"year":1999,"finding":"The Wilms tumor suppressor WT1 (−KTS isoform) directly binds the amphiregulin promoter and acts as a potent transcriptional activator of AREG; recombinant AREG stimulates epithelial branching in embryonic mouse kidney organ cultures, implicating the WT1→AREG axis in kidney differentiation.","method":"Oligonucleotide microarray (gene expression after inducible WT1), reporter assays, EMSA/promoter binding, kidney organ culture with recombinant AREG","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — direct promoter binding confirmed, inducible expression system, organ culture functional validation; published in high-impact journal","pmids":["10490105"],"is_preprint":false},{"year":2000,"finding":"Ectodomain shedding of membrane-anchored EGFR ligands including amphiregulin is required for keratinocyte migration in cutaneous wound healing; wound stimuli induce shedding of HB-EGF as the predominant soluble EGFR ligand; inhibition of shedding with OSU8-1 blocked EGFR activation and keratinocyte migration in vitro and reepithelialization in vivo.","method":"In vitro wound assay, EGFR activation assays, metalloprotease inhibitor (OSU8-1), soluble EGFR-Fc neutralization, mouse wound healing model with rescue by recombinant HB-EGF","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro and in vivo experiments with pharmacological and molecular inhibition plus rescue; mechanistic dissection of ectodomain shedding requirement","pmids":["11038170"],"is_preprint":false},{"year":2003,"finding":"TACE/ADAM17 metalloprotease is the specific enzyme responsible for cleavage and release of amphiregulin from the membrane in response to GPCR agonists (LPA, carbachol); AREG release is required for GPCR-induced EGFR transactivation, downstream mitogenic signaling, cell proliferation, migration, and Akt/PKB survival activation. siRNA silencing of AREG or TACE blocks all these responses.","method":"siRNA gene silencing of AREG and TACE, dominant-negative TACE mutant, neutralizing antibodies, TACE inhibitor (TIMP-3), EGFR phosphorylation assays, cell proliferation and migration assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal approaches (siRNA, dominant-negative, antibody, inhibitor) converging on the same mechanism; replicated across assays","pmids":["12743035"],"is_preprint":false},{"year":2003,"finding":"Tobacco smoke activates ADAM17/TACE via oxygen radical generation, which cleaves transmembrane amphiregulin to produce soluble AREG that binds EGFR and stimulates lung epithelial cell proliferation, defining a smoke→ROS→ADAM17→AREG→EGFR signaling axis.","method":"Cell proliferation assays, ADAM17 inhibitors, ROS scavengers, metalloprotease inhibitors, EGFR inhibitors, smoke condensate stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — pharmacological dissection of the signaling cascade with multiple inhibitors at each step","pmids":["12711607"],"is_preprint":false},{"year":2005,"finding":"AREG is rapidly induced after partial hepatectomy in rodents via IL-1β and prostaglandin E2 (but not HGF, IL-6, or TNF-α); AREG acts as a primary mitogen for hepatocytes through EGFR; AREG-null mice show impaired hepatocyte proliferative responses after partial hepatectomy, demonstrating an essential role for AREG in early liver regeneration.","method":"AREG-null mice, partial hepatectomy model, primary hepatocyte proliferation assays, cytokine stimulation experiments, EGFR inhibition","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — knockout mouse model with defined phenotype, primary cell assays, cytokine specificity established","pmids":["15685553"],"is_preprint":false},{"year":2006,"finding":"AREG maintains a self-sustaining autocrine loop in SUM149 breast cancer cells requiring metalloprotease-dependent cleavage of the membrane precursor; juxtacrine AREG (membrane-anchored, uncleaved) can also activate EGFR in adjacent cells; AREG autocrine signaling promotes cell invasiveness and motility by upregulating invasion/motility genes.","method":"EGFR phosphorylation assays, AR-neutralizing antibodies, pan-ErbB inhibitor CI1033, anti-EGFR antibody C225, metalloprotease inhibitor GM6001, juxtacrine overlay assay, invasion/motility assays, gene expression analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple inhibition approaches distinguishing autocrine vs juxtacrine modes; functional invasion/motility readouts","pmids":["17035230"],"is_preprint":false},{"year":2006,"finding":"The human AREG promoter contains three conserved TCF/LEF binding sites (conserved in chimpanzee but not rodent), identifying AREG as a direct transcriptional target of the canonical WNT/β-catenin signaling pathway; WNT signaling activation may drive AREG upregulation and consequent EGFR ligand-mediated gefitinib resistance.","method":"Bioinformatic promoter analysis, comparative genomics of primate vs. rodent AREG promoters","journal":"International journal of molecular medicine","confidence":"Low","confidence_rationale":"Tier 4 — computational prediction only, no experimental validation of TCF/LEF binding or WNT-induced AREG transcription","pmids":["16685431"],"is_preprint":false},{"year":2009,"finding":"YAP (yes-associated protein), the transcriptional co-activator and Hippo pathway effector, directly induces AREG gene transcription; YAP-expressing cells secrete AREG to stimulate proliferation of neighboring untransfected cells in a non-cell-autonomous manner; AREG-EGFR signaling mediates YAP's proliferative and migratory (but not EMT) effects; suppression of LATS1/2 is sufficient to induce AREG expression.","method":"YAP overexpression in MCF10A cells, AREG knockdown, EGFR kinase inhibitor, co-culture/paracrine proliferation assay, LATS1/2 siRNA knockdown, Drosophila yorkie/EGFR genetic interaction","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (siRNA, inhibitor, co-culture), cross-species genetic validation in Drosophila; published in high-impact journal","pmids":["19935651"],"is_preprint":false},{"year":2011,"finding":"Cancer cells release exosomes containing full-length, signaling-competent AREG; exosomal AREG increases invasiveness of recipient breast cancer cells 4-fold over soluble recombinant AREG, with AREG exosomes displaying significantly greater membrane stability than other EGFR ligands; an average of 24 AREG molecules are packaged per exosome; mutant KRAS elevates exosomal AREG levels.","method":"Exosome isolation, Western blot, quantitative mass spectrometry of exosomal AREG content, invasion assays in recipient cells, MDCK cells expressing individual EGFR ligands, KRAS isogenic cell lines","journal":"Current biology","confidence":"High","confidence_rationale":"Tier 2 — quantitative exosome characterization with functional invasiveness assays; isogenic KRAS comparison; novel mode of EGFR ligand signaling","pmids":["21514161"],"is_preprint":false},{"year":2011,"finding":"HIF-2α drives AREG expression through the endogenous AREG promoter via a non-canonical mechanism lacking a classical HIF-DNA interaction motif (HRE), establishing a novel mode of HIF-mediated gene regulation; HIF-2α-dependent AREG secretion activates EGF receptor family members in an autocrine loop promoting breast cancer cell self-sufficiency.","method":"HIF-2α knockdown/overexpression, ChIP assay on endogenous AREG promoter, EGFR family phosphorylation assays, patient tumor data correlation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — ChIP on endogenous promoter revealing novel mechanism, functional EGFR activation assays","pmids":["21927022"],"is_preprint":false},{"year":2011,"finding":"AREG upregulates MMP-9 in metastatic breast cancer cells and promotes invasion through the MAPK/ERK pathway; MEK inhibition (PD98059) and MAPK antisense oligonucleotides significantly reduce AREG/EGF-induced MMP-9 secretion and invasion, placing AREG upstream of MAPK→MMP-9 in invasion signaling.","method":"MEK inhibitor PD98059, Ras inhibitor, PI3K inhibitor, MAPK antisense oligonucleotides, MMP-9 ELISA, invasion through Matrigel","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and antisense dissection of pathway; multiple inhibitors at different nodes","pmids":["10389762"],"is_preprint":false},{"year":2013,"finding":"The CRTC1-MAML2 fusion oncogene upregulates AREG by co-activating the transcription factor CREB at the AREG promoter; secreted AREG then activates EGFR in an autocrine manner to promote mucoepidermoid carcinoma (MEC) cell growth and survival; CRTC1-MAML2-positive MEC cells are highly sensitive to EGFR inhibition.","method":"RNA interference of CRTC1-MAML2 and AREG, CREB co-activation reporter assay, EGFR inhibitor treatment, xenograft mouse models, gene expression analysis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — siRNA knockdown of oncogene and AREG with functional readouts in vitro and in vivo; CREB-mediated transcriptional mechanism defined","pmids":["23975434"],"is_preprint":false},{"year":2013,"finding":"RASSF1A tumor suppressor activates the Hippo pathway (via MST kinases) to suppress YAP oncogenic activity, resulting in reduced AREG secretion from hepatocellular carcinoma cells; RASSF1A overexpression inhibits HCC cell proliferation and apoptosis induction via this RASSF1A→Hippo→YAP→AREG axis.","method":"RASSF1A overexpression in HCC cells, AREG secretion measurement (ELISA), apoptosis assays, proliferation assays, immunohistochemistry of human specimens","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function with mechanistic pathway placement; confirmed in clinical specimens","pmids":["23594797"],"is_preprint":false},{"year":2017,"finding":"miR-34c-5p directly targets the AREG 3'UTR (confirmed by luciferase reporter and mutant analysis) and suppresses AREG expression; AREG promotes ovarian cancer stemness (sphere formation, self-renewal) and drug resistance via the AREG→EGFR→ERK pathway, which is inhibited by miR-34c-5p.","method":"Luciferase reporter assay with wild-type and mutant AREG 3'UTR, miR-34c-5p overexpression, AREG overexpression, sphere formation assays, drug resistance assays, ERK pathway analysis","journal":"Oncogenesis","confidence":"High","confidence_rationale":"Tier 1–2 — direct 3'UTR targeting confirmed by mutagenesis; functional pathway validated through multiple cell-based assays","pmids":["28459431"],"is_preprint":false},{"year":2019,"finding":"Senescent stromal cells secrete AREG as a SASP (senescence-associated secretory phenotype) component in response to DNA damage; paracrine AREG activates EGFR on cancer cells to mediate acquired chemoresistance; senescent stromal AREG also induces PD-L1 expression in recipient cancer cells, creating immunosuppression; targeting AREG restores chemosensitivity and immunocompetency in humanized animal models.","method":"DNA damage-induced senescence models, AREG neutralization, EGFR inhibition, PD-L1 measurement, drug resistance assays, humanized animal xenograft models","journal":"Aging cell","confidence":"High","confidence_rationale":"Tier 2 — paracrine mechanism defined with multiple functional readouts; in vivo validation in humanized animals","pmids":["31493351"],"is_preprint":false},{"year":2019,"finding":"Multiple myeloma-derived exosomes are enriched in AREG; exosomal AREG activates EGFR in osteoclast precursors, inducing SNAIL mRNA expression; AREG-enriched exosomes promote osteoclast differentiation and block osteoblast differentiation in mesenchymal stromal cells, and stimulate IL-8 release from MSCs to drive osteoclastogenesis indirectly; anti-AREG neutralizing antibody reverses these effects.","method":"Exosome isolation from MM cell lines and patient BM plasma, EGFR activation assays, SNAIL qPCR, anti-AREG neutralizing antibody, OC differentiation assays (RAW264.7 and CD14+ primary cells), MSC co-culture, IL-8 ELISA","journal":"Journal of hematology & oncology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection using primary human cells, patient samples, and antibody neutralization with multiple functional readouts","pmids":["30621731"],"is_preprint":false},{"year":2019,"finding":"AREG expression in granulosa cells is elevated in OHSS patients; exogenous AREG treatment of granulosa cells stimulates VEGF expression and secretion via EGFR/HER2 signaling; siRNA-mediated knockdown of EGFR or AREG attenuates hCG-induced VEGF upregulation, establishing an AREG→EGFR/HER2→VEGF pathway in OHSS pathology.","method":"RT-qPCR of patient granulosa cells, AREG treatment of cultured granulosa cells, siRNA knockdown of EGFR and AREG, VEGF secretion assays","journal":"Biology of reproduction","confidence":"High","confidence_rationale":"Tier 2 — patient-derived cells with siRNA mechanistic validation; AREG→VEGF pathway defined","pmids":["31167229"],"is_preprint":false},{"year":2020,"finding":"AREG mediates epithelial-mesenchymal transition (EMT) in pancreatic cancer via the EGFR→ERK→NF-κB signaling pathway; AREG stimulation increases NF-κB nuclear accumulation; NF-κB inhibitor blocks AREG-induced EMT, migration, and invasion; AREG silencing reduces tumor growth and metastasis in an orthotopic pancreatic cancer model.","method":"siRNA knockdown, exogenous AREG stimulation, wound-healing and Transwell invasion assays, Western blot for EMT markers and pathway components, NF-κB inhibitor, immunofluorescence, orthotopic xenograft model","journal":"Oncology reports","confidence":"High","confidence_rationale":"Tier 2 — loss- and gain-of-function with inhibitor pathway dissection; in vivo orthotopic model validation","pmids":["32323797"],"is_preprint":false},{"year":2021,"finding":"AREG deficiency in mice essentially prevents bleomycin-induced skin fibrosis; bleomycin-induced dermal cell proliferation is absent in Areg-null mice; inhibiting MEK (a downstream effector of AREG-EGFR signaling) with selumetinib effectively blocks skin fibrosis, defining the Areg→EGFR→MEK signaling axis as critical for fibrosis development.","method":"Areg knockout mice, bleomycin-induced skin fibrosis model, histology, cell proliferation markers in dermis, MEK inhibitor (selumetinib) treatment, gene expression comparison between oral mucosa wound healing and skin fibrosis datasets","journal":"Cell & bioscience","confidence":"High","confidence_rationale":"Tier 2 — knockout mouse model with defined phenotype (absence of fibrosis), pharmacological rescue experiment with MEK inhibitor","pmids":["33622407"],"is_preprint":false},{"year":2022,"finding":"IL-17A promotes keratinocyte proliferation in psoriasis by stimulating recruitment of MST1 to the adaptor ACT1, which reduces MST1-LATS1 interaction, leading to YAP dephosphorylation and nuclear accumulation, which then activates AREG transcription; blocking YAP or IL-17A (secukinumab) suppresses the YAP-AREG axis in psoriatic skin.","method":"IL-17A stimulation of HaCaT and NHEK cells, ACT1 co-immunoprecipitation with MST1, YAP phosphorylation assays, AREG expression measurement, imiquimod mouse model, secukinumab treatment in patients","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 — Co-IP defines ACT1-MST1 interaction; mechanistic pathway confirmed in vitro and in vivo; clinical specimen validation","pmids":["35304250"],"is_preprint":false},{"year":2022,"finding":"Mitochondrial dysfunction (loss of mitochondrial transcription factor A, TFAM) dramatically induces AREG expression as a hallmark retrograde signaling response; mitochondrial stress activates enhancers at the AREG locus through c-JUN/YAP1/TEAD axis; BRG1 chromatin remodeler represses these enhancers under normal conditions; this stress-responsive AREG induction is observed in murine liver injury models.","method":"TFAM knockout cells, transcriptomic analysis, ChIP-seq and ATAC-seq (epigenomic), c-JUN/YAP1 co-immunoprecipitation, motif enrichment analysis, mitochondrial stressor treatments, murine liver injury model","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 — multi-omic epigenomic approach with co-IP; genetic and chemical mitochondrial stress models; in vivo liver injury confirmation","pmids":["36095121"],"is_preprint":false},{"year":2022,"finding":"GPR174 negatively regulates AREG expression in regulatory T cells (Tregs) by activating the Gαs/cAMP/PKA signaling pathway, which inhibits nuclear accumulation of EGR1 (early growth response protein 1), a transcriptional activator of AREG; GPR174 deletion in Tregs upregulates AREG, thereby enhancing endothelial cell function and reducing pro-inflammatory macrophage polarization to promote post-ischemic angiogenesis.","method":"Treg-specific GPR174 knockout mice, hindlimb ischemia model, EGR1 nuclear localization assay, cAMP/PKA pathway inhibitors, AREG expression measurement, endothelial cell functional assays, macrophage polarization assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific knockout with defined molecular mechanism (GPR174→Gαs→cAMP→PKA→EGR1→AREG); in vivo angiogenesis phenotype","pmids":["36473866"],"is_preprint":false},{"year":2023,"finding":"METTL3 methyltransferase induces m6A modification on AREG mRNA, stabilizing it and increasing AREG protein levels in pancreatic cancer; miR-33a-3p targets and suppresses METTL3, thereby reducing m6A-stabilization of AREG mRNA and inhibiting pancreatic cancer proliferation, migration, and invasion.","method":"RNA bisulfite sequencing (m6A mapping on AREG mRNA), METTL3 knockdown/overexpression, miR-33a-3p mimic/inhibitor, mRNA stability assays, rescue experiments, migration/invasion assays","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1–2 — direct m6A modification site mapping on AREG mRNA; mechanistic rescue experiments; multiple orthogonal functional assays","pmids":["37604948"],"is_preprint":false},{"year":2011,"finding":"Small molecule inhibitors targeting the COX/AREG/EGFR/ERK autocrine loop (including COX inhibitors, EGFR inhibitors, and MEK/ERK inhibitors) attenuate CMV-induced salivary gland dysplasia, and ERK phosphorylation is required for initial mCMV-induced pathogenesis; this positions AREG as a critical node in CMV-triggered proliferative signaling.","method":"Mouse postnatal salivary gland organ culture model of mCMV infection, pathway-specific small molecule inhibitors (COX inhibitors, EGFR inhibitors, ERK inhibitors), ERK phosphorylation assays","journal":"Experimental and molecular pathology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection of the AREG-containing pathway; organ culture model with defined pathological readout","pmids":["21565184"],"is_preprint":false}],"current_model":"AREG (Amphiregulin) is an EGF family member synthesized as a 252-amino-acid transmembrane precursor that undergoes ectodomain shedding primarily by TACE/ADAM17 to release soluble AREG, which binds EGFR (ErbB1) to activate downstream MAPK/ERK, PI3K/Akt, and NF-κB signaling cascades governing cell survival, proliferation, migration, and EMT; AREG transcription is regulated by multiple upstream inputs including WT1, WNT/β-catenin, HIF-2α, YAP (downstream of the Hippo pathway via LATS1/2), IL-17A→ACT1→MST1→YAP, CRTC1-MAML2/CREB oncofusion, mitochondrial stress via c-JUN/YAP1/TEAD enhancer activation, and GPR174→Gαs/cAMP/PKA→EGR1 in Tregs; AREG can also signal in juxtacrine mode via its membrane-anchored precursor and is packaged into exosomes for paracrine delivery; physiologically, AREG is essential for liver regeneration, keratinocyte-mediated wound healing, and oocyte maturation, while pathologically it drives psoriasis, skin fibrosis (via EGFR→MEK), cancer stemness and chemoresistance (via EGFR→ERK), osteoclastogenesis in myeloma (via exosomal delivery), and immunosuppression through induction of PD-L1 in the tumor microenvironment; AREG mRNA stability is post-transcriptionally regulated by METTL3-mediated m6A modification, and miR-34c-5p directly targets the AREG 3'UTR to suppress its expression."},"narrative":{"teleology":[{"year":1988,"claim":"Identification of AREG as a novel bifunctional growth factor resolved the question of whether breast carcinoma cells secrete factors with both growth-inhibitory and growth-stimulatory activities depending on target cell type.","evidence":"Purification from PMA-treated MCF-7 conditioned medium with bioassays on carcinoma and fibroblast cells","pmids":["3413110"],"confidence":"High","gaps":["Receptor identity unknown","Gene structure unknown","Mechanism of bifunctional activity not defined"]},{"year":1989,"claim":"Sequencing revealed AREG as an EGF-family member that binds EGFR, establishing its receptor specificity and positioning it within the broader EGF ligand family.","evidence":"Complete amino acid sequencing, EGF receptor competition binding assay, keratinocyte growth assay","pmids":["2466334"],"confidence":"High","gaps":["Binding affinity quantification incomplete","Signaling pathway downstream of EGFR not yet mapped","No structure-function dissection of heparin-binding domain"]},{"year":1990,"claim":"Cloning of the AREG gene revealed a 252-amino-acid transmembrane precursor architecture analogous to TGF-α, establishing that AREG is synthesized as a membrane-anchored protein requiring proteolytic processing.","evidence":"Gene cloning, sequencing, chromosomal mapping to 4q13–q21, Northern blot","pmids":["2325643"],"confidence":"High","gaps":["Identity of the processing protease unknown","Whether juxtacrine signaling occurs from unprocessed precursor untested"]},{"year":1996,"claim":"Systematic receptor pairing experiments demonstrated that AREG signals exclusively through EGFR (ErbB1) and does not directly activate ErbB-2, ErbB-3, or ErbB-4, distinguishing it from neuregulins and defining its receptor exclusivity.","evidence":"Ba/F3 cells expressing individual and pairwise ErbB receptors; tyrosine phosphorylation and survival assays","pmids":["8702723"],"confidence":"High","gaps":["Whether AREG induces EGFR heterodimerization with other ErbB members in endogenous contexts not addressed"]},{"year":1997,"claim":"Transgenic keratinocyte-specific AREG overexpression producing a psoriasis-like phenotype established that AREG gain-of-function is sufficient to drive inflammatory hyperproliferative skin disease in vivo.","evidence":"K14 promoter-driven AREG transgenic mice; histological analysis","pmids":["9410906"],"confidence":"High","gaps":["Whether endogenous AREG upregulation is necessary for human psoriasis not tested","Downstream immune cell recruitment mechanism undefined"]},{"year":1999,"claim":"Identification of WT1 as a direct transcriptional activator of the AREG promoter, coupled with AREG's ability to stimulate kidney epithelial branching, linked AREG to developmental morphogenesis downstream of a tumor suppressor.","evidence":"Inducible WT1 expression, EMSA/promoter binding, reporter assays, kidney organ culture with recombinant AREG","pmids":["10490105"],"confidence":"High","gaps":["In vivo requirement for AREG in kidney development not tested via knockout","Other WT1 targets may contribute to branching"]},{"year":2003,"claim":"ADAM17/TACE was identified as the specific sheddase for AREG, and GPCR-induced EGFR transactivation was shown to require TACE-mediated AREG release, solving the long-standing question of how GPCRs activate EGFR.","evidence":"siRNA of AREG and TACE, dominant-negative TACE, TIMP-3 inhibitor, neutralizing antibodies; LPA/carbachol stimulation","pmids":["12743035","12711607"],"confidence":"High","gaps":["Whether other ADAMs contribute under specific conditions not excluded","Structural basis for TACE recognition of AREG cleavage site unknown"]},{"year":2005,"claim":"AREG-null mice revealed an essential, non-redundant role for AREG in hepatocyte proliferation during liver regeneration, induced by IL-1β/PGE2 rather than HGF or IL-6.","evidence":"Areg knockout mice, partial hepatectomy, primary hepatocyte proliferation assays, cytokine stimulation","pmids":["15685553"],"confidence":"High","gaps":["Compensatory upregulation of other EGFR ligands at later time points not fully characterized","Mechanism of IL-1β/PGE2 induction of AREG transcription not defined"]},{"year":2006,"claim":"Demonstration that membrane-anchored AREG activates EGFR in adjacent cells via juxtacrine signaling, in addition to autocrine shedding-dependent signaling, established a dual-mode signaling capability.","evidence":"Juxtacrine overlay assay, metalloprotease inhibitor GM6001, EGFR inhibitors, invasion/motility assays in SUM149 breast cancer cells","pmids":["17035230"],"confidence":"High","gaps":["Relative physiological importance of juxtacrine vs. autocrine signaling in tissues unknown","Structural basis for juxtacrine EGFR activation not resolved"]},{"year":2009,"claim":"YAP was established as a transcriptional inducer of AREG downstream of Hippo pathway suppression, and AREG secretion was shown to mediate YAP's non-cell-autonomous proliferative effects, linking the Hippo pathway to EGFR ligand production.","evidence":"YAP overexpression, AREG knockdown, EGFR inhibitor, co-culture paracrine assay, LATS1/2 siRNA, Drosophila yorkie/EGFR epistasis","pmids":["19935651"],"confidence":"High","gaps":["Whether YAP binds the AREG promoter directly or through TEAD cofactors not resolved at this point","Relative contribution of AREG vs. other YAP targets to organ size control unclear"]},{"year":2011,"claim":"Discovery that cancer-cell-derived exosomes carry signaling-competent AREG that is more potent than soluble AREG in promoting invasiveness revealed an unconventional paracrine delivery mechanism for EGFR ligands.","evidence":"Exosome isolation, quantitative mass spectrometry (~24 AREG/exosome), invasion assays, KRAS isogenic cell lines","pmids":["21514161"],"confidence":"High","gaps":["Mechanism of AREG sorting into exosomes unknown","Whether exosomal AREG is cleaved or full-length transmembrane form not fully resolved","In vivo exosomal AREG bioavailability not quantified"]},{"year":2017,"claim":"miR-34c-5p was shown to directly target the AREG 3′UTR, and AREG→EGFR→ERK signaling was demonstrated to promote cancer stemness and chemoresistance, establishing post-transcriptional control and a functional link to tumor-initiating cell properties.","evidence":"Luciferase reporter with wild-type/mutant AREG 3′UTR, sphere formation, drug resistance assays, ERK pathway analysis in ovarian cancer","pmids":["28459431"],"confidence":"High","gaps":["Broader miRNA regulatory landscape of AREG not mapped","In vivo relevance of miR-34c-5p→AREG axis in chemoresistance untested"]},{"year":2019,"claim":"Senescent stromal cells were found to secrete AREG as a SASP component that confers chemoresistance and induces PD-L1 on cancer cells, establishing AREG as a mediator of the immunosuppressive tumor microenvironment.","evidence":"DNA damage-induced senescence, AREG neutralization, PD-L1 measurement, humanized animal xenograft models","pmids":["31493351"],"confidence":"High","gaps":["Whether AREG-induced PD-L1 operates via NF-κB or another pathway not defined","Clinical relevance of anti-AREG immunosensitization not tested in patients"]},{"year":2019,"claim":"Exosomal AREG from myeloma cells was shown to activate EGFR in osteoclast precursors and suppress osteoblast differentiation, defining a mechanism for myeloma bone disease mediated by AREG-containing exosomes.","evidence":"Exosome isolation from MM cell lines and patient bone marrow, anti-AREG neutralizing antibody, osteoclast differentiation assays, MSC co-culture","pmids":["30621731"],"confidence":"High","gaps":["In vivo bone lesion formation studies with AREG blockade not performed","Whether other exosomal cargo synergizes with AREG not investigated"]},{"year":2021,"claim":"AREG-null mice were completely protected from bleomycin-induced skin fibrosis, and MEK inhibition phenocopied this protection, defining the AREG→EGFR→MEK axis as essential for dermal fibrotic responses.","evidence":"Areg knockout mice, bleomycin fibrosis model, selumetinib (MEK inhibitor), histology and proliferation markers","pmids":["33622407"],"confidence":"High","gaps":["Whether AREG drives fibrosis in other organs (lung, kidney) via the same mechanism untested","Cell source of AREG in fibrotic dermis not identified"]},{"year":2022,"claim":"Multiple studies converged on the transcriptional regulation of AREG: IL-17A→ACT1→MST1→YAP in psoriatic keratinocytes, mitochondrial stress→c-JUN/YAP1/TEAD enhancer activation, and GPR174→Gαs/cAMP/PKA repression of EGR1→AREG in Tregs, revealing context-specific regulatory inputs that funnel through distinct pathways onto the AREG locus.","evidence":"Co-IP of ACT1-MST1, YAP phosphorylation assays, imiquimod mouse model, TFAM knockout with ChIP-seq/ATAC-seq, Treg-specific GPR174 knockout with hindlimb ischemia model","pmids":["35304250","36095121","36473866"],"confidence":"High","gaps":["Relative contribution of each transcriptional input in different tissues not quantified","Enhancer architecture at the AREG locus not fully characterized across cell types","Whether c-JUN/YAP1 and IL-17A/YAP converge on the same enhancer elements not tested"]},{"year":2023,"claim":"METTL3-mediated m6A modification of AREG mRNA was shown to stabilize the transcript and increase AREG protein output, adding an epitranscriptomic layer to AREG regulation.","evidence":"RNA bisulfite sequencing mapping m6A sites on AREG mRNA, METTL3 knockdown/overexpression, mRNA stability assays, rescue experiments in pancreatic cancer cells","pmids":["37604948"],"confidence":"High","gaps":["Identity of the m6A reader protein mediating AREG mRNA stabilization unknown","Whether m6A regulation of AREG is tissue-specific not addressed"]},{"year":null,"claim":"Key unresolved questions include the structural basis for AREG's exclusive EGFR specificity and lower binding affinity compared to EGF, the mechanism by which AREG is selectively sorted into exosomes, whether AREG's juxtacrine versus autocrine/exosomal signaling modes have distinct physiological roles in vivo, and the identity of the m6A reader that stabilizes AREG mRNA.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of AREG-EGFR complex available","Exosomal sorting mechanism of AREG uncharacterized","Relative in vivo contributions of juxtacrine, autocrine, and exosomal AREG signaling undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,5,7,14]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,10,14]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,11,13,17,24]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[17,24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,5,7,11,16,22,26]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[9]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,22,23,26,27]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[14,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[23,30]}],"complexes":[],"partners":["EGFR","ADAM17","YAP1","TEAD","WT1","METTL3","EGR1"],"other_free_text":[]},"mechanistic_narrative":"Amphiregulin (AREG) is an EGF-family ligand synthesized as a 252-amino-acid transmembrane precursor that undergoes ADAM17/TACE-mediated ectodomain shedding to release a soluble heparin-binding growth factor that signals exclusively through EGFR (ErbB1), activating MAPK/ERK, PI3K/Akt, and NF-κB cascades to drive cell proliferation, survival, migration, and epithelial-mesenchymal transition [PMID:2466334, PMID:12743035, PMID:32323797]. AREG transcription is controlled by diverse upstream inputs including WT1, YAP/TEAD (downstream of Hippo/LATS1/2), HIF-2α, CRTC1-MAML2/CREB, IL-17A→ACT1→MST1→YAP, mitochondrial stress via c-JUN/YAP1, and GPR174→Gαs/cAMP/PKA→EGR1 in regulatory T cells, while AREG mRNA stability is post-transcriptionally regulated by METTL3-mediated m6A modification and miR-34c-5p targeting of the 3′UTR [PMID:10490105, PMID:19935651, PMID:35304250, PMID:36095121, PMID:36473866, PMID:37604948, PMID:28459431]. Beyond classical autocrine/paracrine shedding, AREG is packaged into exosomes for intercellular delivery, driving osteoclastogenesis in myeloma bone disease and promoting invasiveness in recipient cancer cells [PMID:21514161, PMID:30621731]. Physiologically, AREG is essential for liver regeneration after partial hepatectomy and for dermal fibrosis downstream of EGFR→MEK signaling, and its overexpression in keratinocytes is sufficient to produce psoriasis-like skin pathology [PMID:15685553, PMID:33622407, PMID:9410906]."},"prefetch_data":{"uniprot":{"accession":"P15514","full_name":"Amphiregulin","aliases":["Colorectum cell-derived growth factor","CRDGF"],"length_aa":252,"mass_kda":27.9,"function":"Ligand of the EGF receptor/EGFR. Autocrine growth factor as well as a mitogen for a broad range of target cells including astrocytes, Schwann cells and fibroblasts","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/P15514/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AREG","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AREG","total_profiled":1310},"omim":[{"mim_id":"614404","title":"RHOMBOID 5 HOMOLOG 2; RHBDF2","url":"https://www.omim.org/entry/614404"},{"mim_id":"603639","title":"A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 17; ADAM17","url":"https://www.omim.org/entry/603639"},{"mim_id":"600345","title":"BETACELLULIN; BTC","url":"https://www.omim.org/entry/600345"},{"mim_id":"148500","title":"TYLOSIS WITH ESOPHAGEAL CANCER; TOC","url":"https://www.omim.org/entry/148500"},{"mim_id":"126150","title":"HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HBEGF","url":"https://www.omim.org/entry/126150"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":122.6},{"tissue":"placenta","ntpm":308.9},{"tissue":"urinary bladder","ntpm":135.5}],"url":"https://www.proteinatlas.org/search/AREG"},"hgnc":{"alias_symbol":["AR","CRDGF"],"prev_symbol":["SDGF","AREGB"]},"alphafold":{"accession":"P15514","domains":[{"cath_id":"2.10.25.10","chopping":"143-185","consensus_level":"medium","plddt":85.4344,"start":143,"end":185}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15514","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15514-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15514-F1-predicted_aligned_error_v6.png","plddt_mean":67.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AREG","jax_strain_url":"https://www.jax.org/strain/search?query=AREG"},"sequence":{"accession":"P15514","fasta_url":"https://rest.uniprot.org/uniprotkb/P15514.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15514/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15514"}},"corpus_meta":[{"pmid":"25184630","id":"PMC_25184630","title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.","date":"2014","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25184630","citation_count":2223,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11943742","id":"PMC_11943742","title":"Androgen receptor (AR) coregulators: an overview.","date":"2002","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11943742","citation_count":706,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26537258","id":"PMC_26537258","title":"Plasma AR and abiraterone-resistant prostate cancer.","date":"2015","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26537258","citation_count":385,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18301781","id":"PMC_18301781","title":"AR, the cell cycle, and prostate cancer.","date":"2008","source":"Nuclear receptor signaling","url":"https://pubmed.ncbi.nlm.nih.gov/18301781","citation_count":270,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23873027","id":"PMC_23873027","title":"Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23873027","citation_count":180,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18612376","id":"PMC_18612376","title":"Diverse roles of androgen receptor (AR) domains in AR-mediated signaling.","date":"2008","source":"Nuclear receptor signaling","url":"https://pubmed.ncbi.nlm.nih.gov/18612376","citation_count":176,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31804827","id":"PMC_31804827","title":"Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31804827","citation_count":162,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28420128","id":"PMC_28420128","title":"AR Signaling and the PI3K Pathway in Prostate Cancer.","date":"2017","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/28420128","citation_count":140,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22245783","id":"PMC_22245783","title":"Androgen receptor (AR) aberrations in castration-resistant prostate cancer.","date":"2012","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22245783","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27565181","id":"PMC_27565181","title":"Cooperative Dynamics of AR and ER Activity in Breast Cancer.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/27565181","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32256939","id":"PMC_32256939","title":"International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants: Impact of air pollution on patients with AR: Current knowledge and future strategies.","date":"2020","source":"The World Allergy Organization journal","url":"https://pubmed.ncbi.nlm.nih.gov/32256939","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30190514","id":"PMC_30190514","title":"Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30190514","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11773441","id":"PMC_11773441","title":"AR and ER interaction with a p21-activated kinase (PAK6).","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11773441","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20980437","id":"PMC_20980437","title":"CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.","date":"2010","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20980437","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11875111","id":"PMC_11875111","title":"Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1.","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11875111","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30995798","id":"PMC_30995798","title":"Everything You Always Wanted to Know about β3-AR * (* But Were Afraid to Ask).","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/30995798","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33093660","id":"PMC_33093660","title":"Binding pathway determines norepinephrine selectivity for the human β1AR over β2AR.","date":"2020","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33093660","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31493351","id":"PMC_31493351","title":"Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.","date":"2019","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/31493351","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30621731","id":"PMC_30621731","title":"Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.","date":"2019","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30621731","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34118355","id":"PMC_34118355","title":"Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34118355","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37038004","id":"PMC_37038004","title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer.","date":"2023","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37038004","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28245550","id":"PMC_28245550","title":"AR Signaling in Breast Cancer.","date":"2017","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/28245550","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32814769","id":"PMC_32814769","title":"Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32814769","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28459431","id":"PMC_28459431","title":"miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway.","date":"2017","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28459431","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33750801","id":"PMC_33750801","title":"A noncanonical AR addiction drives enzalutamide resistance in prostate cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33750801","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33277366","id":"PMC_33277366","title":"KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33277366","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25798840","id":"PMC_25798840","title":"β2-AR signaling controls trastuzumab resistance-dependent pathway.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25798840","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23975434","id":"PMC_23975434","title":"Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23975434","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32868434","id":"PMC_32868434","title":"Analysis of β2AR-Gs and β2AR-Gi complex formation by NMR spectroscopy.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32868434","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21927022","id":"PMC_21927022","title":"Non-canonical HIF-2α function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21927022","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25754347","id":"PMC_25754347","title":"ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25754347","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32323797","id":"PMC_32323797","title":"AREG mediates the epithelial‑mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF‑κB signalling pathway.","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/32323797","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26769913","id":"PMC_26769913","title":"Androgen receptor (AR) in cardiovascular diseases.","date":"2016","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26769913","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28085048","id":"PMC_28085048","title":"AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.","date":"2017","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/28085048","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26728473","id":"PMC_26728473","title":"Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.","date":"2016","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26728473","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27583472","id":"PMC_27583472","title":"Identification of an AR Mutation-Negative Class of Androgen Insensitivity by Determining Endogenous AR Activity.","date":"2016","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27583472","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27991916","id":"PMC_27991916","title":"The HIF/PHF8/AR axis promotes prostate cancer progression.","date":"2016","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27991916","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21782001","id":"PMC_21782001","title":"The AR dependent cell cycle: mechanisms and cancer relevance.","date":"2011","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21782001","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34071114","id":"PMC_34071114","title":"AR Splicing Variants and Resistance to AR Targeting Agents.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34071114","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36169095","id":"PMC_36169095","title":"Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.","date":"2022","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36169095","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30565725","id":"PMC_30565725","title":"Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain.","date":"2018","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30565725","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27449259","id":"PMC_27449259","title":"A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer.","date":"2016","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/27449259","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35304250","id":"PMC_35304250","title":"IL-17A Promotes Psoriasis-Associated Keratinocyte Proliferation through ACT1-Dependent Activation of YAP-AREG Axis.","date":"2022","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35304250","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11818501","id":"PMC_11818501","title":"Domain interactions between coregulator ARA(70) and the androgen receptor (AR).","date":"2002","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11818501","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24053777","id":"PMC_24053777","title":"The transcriptional programme of the androgen receptor (AR) in prostate cancer.","date":"2014","source":"BJU international","url":"https://pubmed.ncbi.nlm.nih.gov/24053777","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11384871","id":"PMC_11384871","title":"The androgen receptor (AR) in syndromes of androgen insensitivity and in prostate cancer.","date":"2001","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11384871","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34545063","id":"PMC_34545063","title":"LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34545063","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36370857","id":"PMC_36370857","title":"METTL3 boosts glycolysis and cardiac fibroblast proliferation by increasing AR methylation.","date":"2022","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36370857","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36588499","id":"PMC_36588499","title":"YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/36588499","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34939643","id":"PMC_34939643","title":"Regulation of AR mRNA translation in response to acute AR pathway inhibition.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/34939643","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26304926","id":"PMC_26304926","title":"Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26304926","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27669432","id":"PMC_27669432","title":"Cell cycle-coupled expansion of AR activity promotes cancer progression.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27669432","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23594797","id":"PMC_23594797","title":"RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma.","date":"2013","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/23594797","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24243687","id":"PMC_24243687","title":"TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.","date":"2014","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24243687","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36473866","id":"PMC_36473866","title":"GPR174 knockdown enhances blood flow recovery in hindlimb ischemia mice model by upregulating AREG expression.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36473866","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38169509","id":"PMC_38169509","title":"ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription.","date":"2024","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/38169509","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32885168","id":"PMC_32885168","title":"ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers.","date":"2020","source":"NAR cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32885168","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29934310","id":"PMC_29934310","title":"Membrane-associated androgen receptor (AR) potentiates its transcriptional activities by activating heat shock protein 27 (HSP27).","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29934310","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23624749","id":"PMC_23624749","title":"Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma.","date":"2013","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23624749","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25382544","id":"PMC_25382544","title":"Identification of AREG and PLK1 pathway modulation as a potential key of the response of intracranial 9L tumor to microbeam radiation therapy.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25382544","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24265091","id":"PMC_24265091","title":"Cholesterol-β1 AR interaction versus cholesterol-β2 AR interaction.","date":"2013","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/24265091","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28536143","id":"PMC_28536143","title":"Aurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28536143","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26742492","id":"PMC_26742492","title":"RYR2, PTDSS1 and AREG genes are implicated in a Lebanese population-based study of copy number variation in autism.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26742492","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25124466","id":"PMC_25124466","title":"Association study of ERβ, AR, and CYP19A1 genes and MtF transsexualism.","date":"2014","source":"The journal of sexual medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25124466","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33083800","id":"PMC_33083800","title":"Sex, androgens and regulation of pulmonary AR, TMPRSS2 and ACE2.","date":"2020","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/33083800","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31167229","id":"PMC_31167229","title":"Upregulation of AREG, EGFR, and HER2 contributes to increased VEGF expression in granulosa cells of patients with OHSS†.","date":"2019","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/31167229","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33926033","id":"PMC_33926033","title":"Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33926033","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37604948","id":"PMC_37604948","title":"miR-33a-3p regulates METTL3-mediated AREG stability and alters EMT to inhibit pancreatic cancer invasion and metastasis.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37604948","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34759344","id":"PMC_34759344","title":"Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34759344","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25158280","id":"PMC_25158280","title":"MEIS1 functions as a potential AR negative regulator.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25158280","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16685431","id":"PMC_16685431","title":"Canonical WNT signaling pathway and human AREG.","date":"2006","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16685431","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1333777","id":"PMC_1333777","title":"Colorectum cell-derived growth factor (CRDGF) is homologous to amphiregulin, a member of the epidermal growth factor family.","date":"1992","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/1333777","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31359506","id":"PMC_31359506","title":"Revisiting the relationships of 2D:4D with androgen receptor (AR) gene and current testosterone levels: Replication study and meta-analyses.","date":"2019","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/31359506","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2787992","id":"PMC_2787992","title":"Effects of smooth muscle cell derived growth factor (SDGF) in combination with other growth factors on smooth muscle cells.","date":"1989","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/2787992","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33921329","id":"PMC_33921329","title":"Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/33921329","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33069193","id":"PMC_33069193","title":"Natural Compounds as Source of Aldose Reductase (AR) Inhibitors for the Treatment of Diabetic Complications: A Mini Review.","date":"2020","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33069193","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36060957","id":"PMC_36060957","title":"Lysine Acetyltransferases and Their Role in AR Signaling and Prostate Cancer.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36060957","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31031857","id":"PMC_31031857","title":"Significance of Amphiregulin (AREG) for the Outcome of Low and High Grade Astrocytoma Patients.","date":"2019","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31031857","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35996853","id":"PMC_35996853","title":"Mammalian adipogenesis regulator (Areg) cells use retinoic acid signalling to be non- and anti-adipogenic in age-dependent manner.","date":"2022","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/35996853","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17166536","id":"PMC_17166536","title":"Hic-5/ARA55: a prostate stroma-specific AR coactivator.","date":"2006","source":"Steroids","url":"https://pubmed.ncbi.nlm.nih.gov/17166536","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29664547","id":"PMC_29664547","title":"HSD3B2, HSD17B1, HSD17B2, ESR1, ESR2 and AR expression in infertile women with endometriosis.","date":"2018","source":"Ginekologia polska","url":"https://pubmed.ncbi.nlm.nih.gov/29664547","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35233061","id":"PMC_35233061","title":"OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/35233061","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33708629","id":"PMC_33708629","title":"Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33708629","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29346310","id":"PMC_29346310","title":"AR Signaling in Human Malignancies: Prostate Cancer and Beyond.","date":"2018","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/29346310","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7590736","id":"PMC_7590736","title":"Mouse chromosomal location of three EGF receptor ligands: amphiregulin (Areg), betacellulin (Btc), and heparin-binding EGF (Hegfl).","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7590736","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24130878","id":"PMC_24130878","title":"Direct interaction between AR and PAK6 in androgen-stimulated PAK6 activation.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24130878","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36095121","id":"PMC_36095121","title":"Mitochondrial stress induces AREG expression and epigenomic remodeling through c-JUN and YAP-mediated enhancer activation.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/36095121","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31616657","id":"PMC_31616657","title":"Non-nuclear AR Signaling in Prostate Cancer.","date":"2019","source":"Frontiers in chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31616657","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33622407","id":"PMC_33622407","title":"A critical role of AREG for bleomycin-induced skin fibrosis.","date":"2021","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/33622407","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29707137","id":"PMC_29707137","title":"CNPY2 inhibits MYLIP-mediated AR protein degradation in prostate cancer cells.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29707137","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31693867","id":"PMC_31693867","title":"DUSP22 suppresses prostate cancer proliferation by targeting the EGFR-AR axis.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31693867","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21565184","id":"PMC_21565184","title":"Small molecule inhibitors of the host cell COX/AREG/EGFR/ERK pathway attenuate cytomegalovirus-induced pathogenesis.","date":"2011","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21565184","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29181434","id":"PMC_29181434","title":"Androgen receptor (AR) cistrome in prostate differentiation and cancer progression.","date":"2017","source":"American journal of clinical and experimental urology","url":"https://pubmed.ncbi.nlm.nih.gov/29181434","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27743893","id":"PMC_27743893","title":"Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.","date":"2016","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27743893","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32742925","id":"PMC_32742925","title":"Coordinated AR and microRNA regulation in prostate cancer.","date":"2020","source":"Asian journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/32742925","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33753989","id":"PMC_33753989","title":"Androgen receptor (AR) decreases HCC cells migration and invasion via miR-325/ACP5 signaling.","date":"2021","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33753989","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17413443","id":"PMC_17413443","title":"Association between CCK-AR gene and schizophrenia with auditory hallucinations.","date":"2007","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17413443","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36408179","id":"PMC_36408179","title":"Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36408179","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38531438","id":"PMC_38531438","title":"Capsaicin induces ATP-dependent thermogenesis via the activation of TRPV1/β3-AR/α1-AR in 3T3-L1 adipocytes and mouse model.","date":"2024","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/38531438","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21130868","id":"PMC_21130868","title":"Intracellular adaptor molecules and AR signalling in the tumour microenvironment.","date":"2010","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/21130868","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16713569","id":"PMC_16713569","title":"A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16713569","citation_count":610,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2466334","id":"PMC_2466334","title":"Structure and function of human amphiregulin: a member of the epidermal growth factor family.","date":"1989","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2466334","citation_count":550,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33845483","id":"PMC_33845483","title":"Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33845483","citation_count":532,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19935651","id":"PMC_19935651","title":"YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway.","date":"2009","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19935651","citation_count":356,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2325643","id":"PMC_2325643","title":"The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2325643","citation_count":356,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3413110","id":"PMC_3413110","title":"Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3413110","citation_count":330,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21514161","id":"PMC_21514161","title":"Amphiregulin exosomes increase cancer cell invasion.","date":"2011","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/21514161","citation_count":285,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12743035","id":"PMC_12743035","title":"TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12743035","citation_count":283,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24463227","id":"PMC_24463227","title":"Amphiregulin.","date":"2014","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/24463227","citation_count":257,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11038170","id":"PMC_11038170","title":"Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing.","date":"2000","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11038170","citation_count":246,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10490105","id":"PMC_10490105","title":"The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin.","date":"1999","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10490105","citation_count":238,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2017164","id":"PMC_2017164","title":"A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2017164","citation_count":235,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21658434","id":"PMC_21658434","title":"The multiple roles of amphiregulin in human cancer.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21658434","citation_count":225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9410906","id":"PMC_9410906","title":"Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype.","date":"1997","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/9410906","citation_count":183,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15685553","id":"PMC_15685553","title":"Amphiregulin: an early trigger of liver regeneration in mice.","date":"2005","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15685553","citation_count":165,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8702723","id":"PMC_8702723","title":"The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8702723","citation_count":153,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12711607","id":"PMC_12711607","title":"Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12711607","citation_count":151,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2234093","id":"PMC_2234093","title":"Structure, expression and function of a schwannoma-derived growth factor.","date":"1990","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2234093","citation_count":149,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10389762","id":"PMC_10389762","title":"Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10389762","citation_count":133,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21832049","id":"PMC_21832049","title":"Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha-synuclein.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21832049","citation_count":131,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17035230","id":"PMC_17035230","title":"Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17035230","citation_count":130,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47003,"output_tokens":4143,"usd":0.101577},"stage2":{"model":"claude-opus-4-6","input_tokens":7662,"output_tokens":3618,"usd":0.19314},"total_usd":0.72024,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":59847,"output_tokens":10230,"usd":0.166495},"round2_rules_fired":"R2,R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12727,"output_tokens":4362,"usd":0.259028}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2019,\n      \"finding\": \"Senescent stromal cell-derived AREG activates EGFR signaling in recipient cancer cells to confer chemoresistance, and paracrine AREG induces PD-L1 expression in cancer cells, creating an immunosuppressive tumor microenvironment; targeting AREG reduced chemoresistance and restored immunocompetency in humanized animal models.\",\n      \"method\": \"SASP factor neutralization, siRNA knockdown, ELISA, flow cytometry, humanized animal models\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (neutralizing antibody, siRNA KD, in vivo models) in a single study with defined mechanistic pathway\",\n      \"pmids\": [\"31493351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The CRTC1-MAML2 fusion oncogene upregulates AREG expression by co-activating the transcription factor CREB, and AREG subsequently activates EGFR signaling in an autocrine manner to promote mucoepidermoid carcinoma (MEC) cell growth and survival; MEC cells were highly sensitive to EGFR inhibition.\",\n      \"method\": \"Gene expression analysis, RNA interference, pharmacological EGFR inhibition, xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established via RNAi + pharmacological inhibition + in vivo validation with defined molecular pathway\",\n      \"pmids\": [\"23975434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-34c-5p directly targets the 3'UTR of AREG mRNA (confirmed by luciferase reporter and mutant analysis), thereby downregulating the AREG-EGFR-ERK pathway to inhibit ovarian cancer stemness and drug resistance.\",\n      \"method\": \"Luciferase reporter assay, mutant analysis, qRT-PCR, sphere formation assay, drug resistance assay, in vivo tumorigenicity\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — direct 3'UTR binding validated by luciferase + mutagenesis, functional rescue experiments, in vivo data\",\n      \"pmids\": [\"28459431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HIF-2α drives AREG expression through a non-canonical mechanism (without classical HIF-DNA interaction motif) at the endogenous AREG promoter, and loss of AREG in HIF-2α-depleted breast cancer cells reduces activation of EGF receptor family members, establishing an HIF-2α/AREG autocrine growth signaling loop.\",\n      \"method\": \"HIF-2α siRNA knockdown, ChIP, EGFR family phosphorylation assays, promoter analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating endogenous promoter recruitment + loss-of-function with defined downstream signaling readout\",\n      \"pmids\": [\"21927022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RASSF1A overexpression activates the Hippo pathway (via MST kinases), suppressing YAP oncogenic function and leading to significantly reduced AREG secretion in hepatocellular carcinoma (HCC) cells; YAP and AREG were confirmed as functionally downstream targets of RASSF1A in the Hippo pathway.\",\n      \"method\": \"RASSF1A overexpression, Hippo pathway activation assays, AREG secretion ELISA, human HCC tissue analysis\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (RASSF1A→MST→YAP→AREG) with secretion readout, single lab study\",\n      \"pmids\": [\"23594797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Multiple myeloma-derived exosomes are enriched for AREG, which activates EGFR in osteoclast precursors (upregulating SNAIL mRNA), promoting osteoclast differentiation; anti-AREG neutralizing antibody blocked this effect. AREG-enriched exosomes also inhibit osteoblast differentiation and increase IL-8 release from mesenchymal stromal cells.\",\n      \"method\": \"Exosome isolation, ELISA, RT-PCR, anti-AREG neutralizing mAb, RAW264.7 and primary CD14+ osteoclast differentiation assays, MSC co-culture\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell types, neutralizing antibody rescue, patient-derived samples, mechanistically defined EGFR/SNAIL pathway\",\n      \"pmids\": [\"30621731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AREG mediates epithelial-mesenchymal transition (EMT) in pancreatic cancer cells via the EGFR/ERK/NF-κB signaling pathway; AREG stimulation increased nuclear NF-κB accumulation through EGFR/ERK, inducing EMT markers; an NF-κB inhibitor blocked AREG-induced EMT, migration and invasion. AREG silencing reduced tumor growth and metastasis in an orthotopic model.\",\n      \"method\": \"siRNA knockdown, exogenous AREG treatment, western blot, immunofluorescence, NF-κB inhibitor, orthotopic mouse model, wound-healing/Transwell assays\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with pharmacological pathway inhibition, in vivo validation, multiple orthogonal readouts\",\n      \"pmids\": [\"32323797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL-17A promotes keratinocyte proliferation in psoriasis through the ACT1-dependent YAP-AREG axis: IL-17A stimulates ACT1 to recruit MST1, reducing MST1-LATS1 interaction, leading to YAP dephosphorylation and increased AREG expression.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, in vivo imiquimod/IL-17A mouse model, HaCaT cell assays, phosphorylation analysis\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway (ACT1→MST1→LATS1→YAP→AREG) established by Co-IP and in vitro/in vivo functional data\",\n      \"pmids\": [\"35304250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Mitochondrial dysfunction (loss of TFAM) induces AREG expression via activation of c-JUN/YAP1/TEAD-mediated enhancers; BRG1 normally represses these enhancers. Epigenomic remodeling at AREG gene enhancers is a hallmark response to mitochondrial stress in hepatic cells.\",\n      \"method\": \"Transcriptomic analysis, ChIP-seq, epigenomic/informatic approaches, enhancer reporter assays, motif analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq defining enhancer occupancy by c-JUN/YAP1/TEAD, combined with transcriptomic and functional data\",\n      \"pmids\": [\"36095121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AREG deficiency (knockout mice) essentially prevents bleomycin-induced skin fibrosis; bleomycin-induced dermal cell proliferation was absent in Areg null mice. Pharmacological MEK inhibition (selumetinib) also blocked fibrosis, defining an AREG-EGFR-MEK signaling axis as critical for skin fibrosis development.\",\n      \"method\": \"Areg knockout mice, bleomycin-induced fibrosis model, histology, MEK inhibitor (selumetinib), cell proliferation assays\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific phenotypic rescue, pharmacological pathway inhibition, in vivo model\",\n      \"pmids\": [\"33622407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GPR174 negatively regulates AREG expression in regulatory T cells (Tregs) by activating the Gαs/cAMP/PKA pathway, which prevents nuclear accumulation of EGR1 (the transcriptional activator of AREG); GPR174 knockout in Tregs upregulates AREG, enhancing endothelial cell function and blood flow recovery after hindlimb ischemia.\",\n      \"method\": \"Conditional GPR174 knockout mice, hindlimb ischemia model, Gαs/cAMP/PKA pathway inhibitors, EGR1 nuclear localization assays, endothelial functional assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined pathway (GPR174→Gαs/cAMP/PKA→EGR1→AREG), in vivo physiological readout\",\n      \"pmids\": [\"36473866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AREG upregulation in granulosa cells of OHSS patients is associated with increased VEGF; exogenous AREG treatment stimulates VEGF expression and secretion in cultured granulosa cells; siRNA-mediated knockdown of EGFR and AREG attenuated hCG-induced VEGF upregulation, establishing AREG as an upstream regulator of VEGF via EGFR/HER2 signaling in OHSS pathogenesis.\",\n      \"method\": \"RT-qPCR, western blot, ELISA, siRNA knockdown of EGFR and AREG, exogenous AREG treatment of granulosa cells\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown + exogenous treatment with defined downstream VEGF readout, single lab\",\n      \"pmids\": [\"31167229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Canonical WNT/β-catenin signaling can transcriptionally activate AREG: three TCF/LEF-binding sites were identified within the human AREG promoter (conserved in chimpanzee but not rodent), suggesting WNT pathway activation leads to AREG upregulation and potentially gefitinib resistance.\",\n      \"method\": \"Bioinformatics/comparative genomics analysis of AREG promoter, TCF/LEF binding site identification\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational/comparative genomics only, no functional validation of TCF/LEF binding\",\n      \"pmids\": [\"16685431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"AREG (amphiregulin/CRDGF) binds and activates the EGF receptor (EGFR), stimulating EGFR tyrosine kinase phosphorylation, establishing AREG as a functional EGFR ligand.\",\n      \"method\": \"Protein purification, N-terminal sequencing, western blot with anti-AR antiserum, EGFR tyrosine phosphorylation assay\",\n      \"journal\": \"Growth factors (Chur, Switzerland)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical purification, identity confirmation, and direct receptor kinase activation assay\",\n      \"pmids\": [\"1333777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"METTL3 induces m6A modification on AREG mRNA, facilitating AREG mRNA stability; miR-33a-3p inhibits METTL3, thereby reducing m6A-mediated AREG stabilization and suppressing pancreatic cancer invasion and metastasis.\",\n      \"method\": \"RNA bisulfite sequencing, RIP-qPCR, EMSA, miRNA luciferase reporter assay, in vitro m6A modification assay, METTL3 knockdown\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA-BisSeq and RIP-qPCR identify m6A sites, EMSA confirms binding, single lab\",\n      \"pmids\": [\"37604948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In a mouse salivary gland CMV dysplasia model, the COX-2/AREG/EGFR/ERK autocrine loop is required for CMV-induced pathogenesis; small molecule inhibitors targeting steps in this pathway (including ERK phosphorylation and ErbB receptor signaling) ameliorated CMV-induced pathology.\",\n      \"method\": \"Mouse postnatal SMG organ culture, small molecule inhibitors of COX, EGFR, and ERK, phosphorylation assays\",\n      \"journal\": \"Experimental and molecular pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological pathway dissection in organ culture model with defined AREG-containing autocrine loop\",\n      \"pmids\": [\"21565184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Mouse Areg and Btc are tightly linked on mouse chromosome 5; chromosomal mapping also provided evidence that Sdgf (smooth muscle cell-derived growth factor) is a species variant of Areg, establishing their molecular identity.\",\n      \"method\": \"Mouse chromosomal mapping, genomic linkage analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic mapping with species identity confirmation, foundational genomic characterization\",\n      \"pmids\": [\"7590736\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AREG (amphiregulin) is a secreted EGF-family ligand that binds and activates EGFR/ErbB receptors to stimulate downstream ERK, NF-κB, and other mitogenic pathways in autocrine and paracrine fashions; its expression is transcriptionally regulated by HIF-2α, WNT/β-catenin (via TCF/LEF sites), YAP/TEAD (downstream of Hippo signaling and triggered by IL-17A via ACT1→MST1 or by mitochondrial stress via c-JUN/YAP1), and CRTC1-MAML2/CREB oncofusion, while its mRNA stability is post-transcriptionally controlled by METTL3-mediated m6A modification; AREG mediates pro-tumorigenic processes including EMT, cancer stemness, chemoresistance, PD-L1-dependent immunosuppression, osteoclastogenesis, and tissue fibrosis, and is genetically required for bleomycin-induced skin fibrosis in vivo.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**Classification:**\n\nThe target gene is AREG (Amphiregulin), the EGF family ligand/protein-coding gene.\n\nPapers about \"AR\" (androgen receptor), \"β-AR\" (beta-adrenergic receptor), \"CCK-AR\" (cholecystokinin receptor), \"Areg\" (adipogenesis regulator cells), or \"AR\" (aldose reductase) are ALIAS COLLISIONS → EXCLUDE.\n\nKEEP papers (about AREG/Amphiregulin protein):\n- [18] PMID:31493351 (senescent stromal AREG, EGFR, PD-L1)\n- [19] PMID:30621731 (MM exosomes, AREG, osteoclastogenesis)\n- [24] PMID:28459431 (miR-34c-5p, AREG-EGFR-ERK, ovarian cancer stemness)\n- [28] PMID:23975434 (CRTC1-MAML2, AREG-EGFR, MEC)\n- [30] PMID:21927022 (HIF-2α, AREG, EGFR autocrine)\n- [32] PMID:32323797 (AREG, EMT, EGFR/ERK/NF-κB, pancreatic cancer)\n- [43] PMID:35304250 (IL-17A, ACT1, YAP-AREG, psoriasis)\n- [53] PMID:23594797 (RASSF1A, Hippo, YAP, AREG, HCC)\n- [55] PMID:36473866 (GPR174, AREG, EGR1, angiogenesis)\n- [59] PMID:23624749 (AREG methylation, glioblastoma - expression study, EXCLUDE for mechanism)\n- [60] PMID:25382544 (AREG in MRT response - expression/transcriptomic, EXCLUDE)\n- [63] PMID:26742492 (CNV, AREG in autism - genetic association, EXCLUDE)\n- [66] PMID:31167229 (AREG, EGFR, HER2, VEGF, OHSS)\n- [68] PMID:37604948 (miR-33a-3p, METTL3, AREG m6A, pancreatic cancer)\n- [71] PMID:16685431 (WNT/TCF/LEF, AREG promoter)\n- [78] PMID:31031857 (AREG expression in astrocytoma - mostly expression, some mechanism)\n- [79] PMID:35996853 (\"Areg\" = adipogenesis regulator cells, CD142+ ASPCs → EXCLUDE: this is a cell population named \"Areg\", not the AREG protein)\n- [85] PMID:7590736 (chromosomal mapping of Areg, Btc, Hegfl - KEEP as foundational genomic)\n- [87] PMID:36095121 (mitochondrial stress, c-JUN/YAP, AREG enhancer)\n- [89] PMID:33622407 (AREG, bleomycin, skin fibrosis, MEK)\n- [92] PMID:21565184 (COX/AREG/EGFR/ERK, CMV pathogenesis)\n\nGene2pubmed KEEP papers:\n- [10] PMID:2466334 (structure/function of amphiregulin)\n- [13] PMID:19935651 (YAP-AREG, Hippo pathway)\n- [14] PMID:2325643 (AREG gene, transmembrane precursor, EGF family)\n- [15] PMID:3413110 (original isolation of amphiregulin)\n- [16] PMID:21514161 (AREG exosomes, cancer invasion)\n- [17] PMID:12743035 (TACE cleavage of proamphiregulin, GPCR→EGFR)\n- [18] PMID:24463227 (AREG review - foundational mechanistic)\n- [19] PMID:11038170 (ectodomain shedding, EGFR ligands, wound healing)\n- [20] PMID:10490105 (WT1 transcriptional activator of amphiregulin)\n- [21] PMID:2017164 (KAF=amphiregulin, heparin sulfate inhibition)\n- [22] PMID:21658434 (multiple roles of AREG in cancer - review)\n- [23] PMID:9410906 (transgenic AR expression, psoriasis phenotype)\n- [24] PMID:15685553 (AREG in liver regeneration)\n- [25] PMID:8702723 (AREG couples EGFR to Neu/ErbB-3/ErbB-4)\n- [26] PMID:12711607 (tobacco smoke, ADAM17, amphiregulin, EGFR, proliferation)\n- [27] PMID:2234093 (SDGF=amphiregulin, schwannoma)\n- [28] PMID:10389762 (EGF/amphiregulin, MAPK, MMP-9)\n- [30] PMID:17035230 (AREG autocrine loop, breast cancer, metalloprotease cleavage)\n\nEXCLUDE (alias collisions - androgen receptor AR, beta-AR, CCK-AR, aldose reductase AR, \"Areg\" adipogenesis cells):\nPapers [1]-[12], [16] (β2-AR), [17] (β1AR/β2AR), [20], [21], [22], [23], [25], [26], [27] (β2-AR), [29] (β2AR), [31]-[42] (AR=androgen receptor), [44]-[52], [54], [56]-[58], [61] (β-AR), [62]-[65], [67], [69]-[70], [72]-[77], [80]-[84], [86], [88], [90]-[91], [93]-[96], [97] (CCK-AR), [98]-[100] (β3-AR), gene2pubmed [1]-[9], [11]-[12], [29]\n\nNow extracting discoveries from KEPT papers:\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"Amphiregulin (AREG) was purified to homogeneity from conditioned medium of PMA-treated MCF-7 human breast carcinoma cells as a bifunctional glycoprotein that inhibits growth of certain human carcinoma cells while stimulating proliferation of human fibroblasts and other tumor cells; biological activity requires intact disulfide bonds.\",\n      \"method\": \"Protein purification (heparin affinity, HPLC, gel permeation), SDS-PAGE, bioassays, chemical modification\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original purification to homogeneity with functional characterization using multiple orthogonal methods\",\n      \"pmids\": [\"3413110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Amphiregulin is a 78–84 amino acid protein whose C-terminal half (residues 46–84) is homologous to the EGF family, while the N-terminal half is unusually hydrophilic and heparin-binding; it binds the EGF receptor but with lower affinity than EGF and fully substitutes for EGF in murine keratinocyte growth.\",\n      \"method\": \"Protein sequencing, receptor binding competition assay, keratinocyte growth assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete amino acid sequence determination with receptor binding and functional assays; foundational structure-function study\",\n      \"pmids\": [\"2466334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The AREG gene encodes a 252-amino-acid transmembrane precursor (similar to TGF-α precursor organization) from which the mature 84-aa protein is derived; AREG gene was localized to chromosomal region 4q13–4q21; AREG exhibits tumor-inhibitory activity on aggressive carcinoma lines while promoting normal epithelial cell growth.\",\n      \"method\": \"Gene cloning and sequencing, Northern blot, chromosomal mapping, cell growth assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — gene structure determination with functional characterization, replicated by multiple labs\",\n      \"pmids\": [\"2325643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Schwannoma-derived growth factor (SDGF) is identical to amphiregulin and functions as an autocrine mitogen for Schwann cells and a mitogen for astrocytes and fibroblasts, demonstrating AREG's role in the nervous system.\",\n      \"method\": \"Protein purification, sequence determination, mitogenesis assays on glial cells and fibroblasts\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purification and sequencing confirming identity; functional assays across multiple cell types\",\n      \"pmids\": [\"2234093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Keratinocyte autocrine factor (KAF) is identical to amphiregulin; heparin sulfate inhibits AREG mitogenic activity by blocking its ability to compete with EGF for cell surface binding, establishing a negative regulatory mechanism for AREG signaling.\",\n      \"method\": \"Protein purification, N-terminal microsequencing, ELISA, competitive binding assay, cell proliferation assay with heparin sulfate\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — identity confirmed by sequencing and ELISA; heparin inhibition mechanism directly demonstrated\",\n      \"pmids\": [\"2017164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"CRDGF (colorectum cell-derived growth factor) produced by HT29 colon cancer cells is identical to amphiregulin; AREG stimulates phosphorylation of the EGF receptor on tyrosine residues, indicating the AR intracellular signaling pathway involves activation of EGF-R kinase.\",\n      \"method\": \"Protein purification, N-terminal sequencing, Western blot with AR-specific antiserum, EGF receptor phosphorylation assay\",\n      \"journal\": \"Growth factors\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct EGF-R tyrosine phosphorylation demonstrated by biochemical assay; identity confirmed by sequencing and immunoblot\",\n      \"pmids\": [\"1333777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Areg and Btc (betacellulin) are tightly linked on mouse chromosome 5; a previously described growth factor SDGF is confirmed as a species variant of Areg, clarifying the evolutionary relationships within the EGF ligand family.\",\n      \"method\": \"Interspecific backcross mapping, genomic analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic mapping; confirms SDGF/AREG identity through genomic evidence\",\n      \"pmids\": [\"7590736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"AREG, like EGF, TGF-α, and HB-EGF, couples primarily through EGFR (ErbB1) to drive tyrosine phosphorylation and physiological proliferative responses; these ligands do not directly activate ErbB-2 (Neu) alone but require EGFR as an intermediary, distinguishing them functionally from neuregulins which directly bind ErbB-3/4.\",\n      \"method\": \"Ba/F3 cell lines expressing single and pairwise ErbB receptors, receptor tyrosine phosphorylation assays, IL-3-independent survival/proliferation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted receptor-specific signaling using defined cell panels with rigorous comparison across all four ErbB family members\",\n      \"pmids\": [\"8702723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Transgenic overexpression of human AREG driven by the keratin-14 promoter in basal keratinocytes induces a psoriasis-like skin phenotype with hyperkeratosis, acanthosis, and inflammatory infiltration, establishing that aberrant AREG expression is sufficient to drive psoriatic-like pathology in vivo.\",\n      \"method\": \"Transgenic mouse model (K14-ARGE), histological analysis, phenotypic characterization\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain-of-function with defined cellular phenotype; links AREG expression directly to skin pathology\",\n      \"pmids\": [\"9410906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The Wilms tumor suppressor WT1 (−KTS isoform) directly binds the amphiregulin promoter and acts as a potent transcriptional activator of AREG; recombinant AREG stimulates epithelial branching in embryonic mouse kidney organ cultures, implicating the WT1→AREG axis in kidney differentiation.\",\n      \"method\": \"Oligonucleotide microarray (gene expression after inducible WT1), reporter assays, EMSA/promoter binding, kidney organ culture with recombinant AREG\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct promoter binding confirmed, inducible expression system, organ culture functional validation; published in high-impact journal\",\n      \"pmids\": [\"10490105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Ectodomain shedding of membrane-anchored EGFR ligands including amphiregulin is required for keratinocyte migration in cutaneous wound healing; wound stimuli induce shedding of HB-EGF as the predominant soluble EGFR ligand; inhibition of shedding with OSU8-1 blocked EGFR activation and keratinocyte migration in vitro and reepithelialization in vivo.\",\n      \"method\": \"In vitro wound assay, EGFR activation assays, metalloprotease inhibitor (OSU8-1), soluble EGFR-Fc neutralization, mouse wound healing model with rescue by recombinant HB-EGF\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro and in vivo experiments with pharmacological and molecular inhibition plus rescue; mechanistic dissection of ectodomain shedding requirement\",\n      \"pmids\": [\"11038170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TACE/ADAM17 metalloprotease is the specific enzyme responsible for cleavage and release of amphiregulin from the membrane in response to GPCR agonists (LPA, carbachol); AREG release is required for GPCR-induced EGFR transactivation, downstream mitogenic signaling, cell proliferation, migration, and Akt/PKB survival activation. siRNA silencing of AREG or TACE blocks all these responses.\",\n      \"method\": \"siRNA gene silencing of AREG and TACE, dominant-negative TACE mutant, neutralizing antibodies, TACE inhibitor (TIMP-3), EGFR phosphorylation assays, cell proliferation and migration assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal approaches (siRNA, dominant-negative, antibody, inhibitor) converging on the same mechanism; replicated across assays\",\n      \"pmids\": [\"12743035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Tobacco smoke activates ADAM17/TACE via oxygen radical generation, which cleaves transmembrane amphiregulin to produce soluble AREG that binds EGFR and stimulates lung epithelial cell proliferation, defining a smoke→ROS→ADAM17→AREG→EGFR signaling axis.\",\n      \"method\": \"Cell proliferation assays, ADAM17 inhibitors, ROS scavengers, metalloprotease inhibitors, EGFR inhibitors, smoke condensate stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of the signaling cascade with multiple inhibitors at each step\",\n      \"pmids\": [\"12711607\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"AREG is rapidly induced after partial hepatectomy in rodents via IL-1β and prostaglandin E2 (but not HGF, IL-6, or TNF-α); AREG acts as a primary mitogen for hepatocytes through EGFR; AREG-null mice show impaired hepatocyte proliferative responses after partial hepatectomy, demonstrating an essential role for AREG in early liver regeneration.\",\n      \"method\": \"AREG-null mice, partial hepatectomy model, primary hepatocyte proliferation assays, cytokine stimulation experiments, EGFR inhibition\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockout mouse model with defined phenotype, primary cell assays, cytokine specificity established\",\n      \"pmids\": [\"15685553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"AREG maintains a self-sustaining autocrine loop in SUM149 breast cancer cells requiring metalloprotease-dependent cleavage of the membrane precursor; juxtacrine AREG (membrane-anchored, uncleaved) can also activate EGFR in adjacent cells; AREG autocrine signaling promotes cell invasiveness and motility by upregulating invasion/motility genes.\",\n      \"method\": \"EGFR phosphorylation assays, AR-neutralizing antibodies, pan-ErbB inhibitor CI1033, anti-EGFR antibody C225, metalloprotease inhibitor GM6001, juxtacrine overlay assay, invasion/motility assays, gene expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibition approaches distinguishing autocrine vs juxtacrine modes; functional invasion/motility readouts\",\n      \"pmids\": [\"17035230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The human AREG promoter contains three conserved TCF/LEF binding sites (conserved in chimpanzee but not rodent), identifying AREG as a direct transcriptional target of the canonical WNT/β-catenin signaling pathway; WNT signaling activation may drive AREG upregulation and consequent EGFR ligand-mediated gefitinib resistance.\",\n      \"method\": \"Bioinformatic promoter analysis, comparative genomics of primate vs. rodent AREG promoters\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction only, no experimental validation of TCF/LEF binding or WNT-induced AREG transcription\",\n      \"pmids\": [\"16685431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"YAP (yes-associated protein), the transcriptional co-activator and Hippo pathway effector, directly induces AREG gene transcription; YAP-expressing cells secrete AREG to stimulate proliferation of neighboring untransfected cells in a non-cell-autonomous manner; AREG-EGFR signaling mediates YAP's proliferative and migratory (but not EMT) effects; suppression of LATS1/2 is sufficient to induce AREG expression.\",\n      \"method\": \"YAP overexpression in MCF10A cells, AREG knockdown, EGFR kinase inhibitor, co-culture/paracrine proliferation assay, LATS1/2 siRNA knockdown, Drosophila yorkie/EGFR genetic interaction\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (siRNA, inhibitor, co-culture), cross-species genetic validation in Drosophila; published in high-impact journal\",\n      \"pmids\": [\"19935651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Cancer cells release exosomes containing full-length, signaling-competent AREG; exosomal AREG increases invasiveness of recipient breast cancer cells 4-fold over soluble recombinant AREG, with AREG exosomes displaying significantly greater membrane stability than other EGFR ligands; an average of 24 AREG molecules are packaged per exosome; mutant KRAS elevates exosomal AREG levels.\",\n      \"method\": \"Exosome isolation, Western blot, quantitative mass spectrometry of exosomal AREG content, invasion assays in recipient cells, MDCK cells expressing individual EGFR ligands, KRAS isogenic cell lines\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative exosome characterization with functional invasiveness assays; isogenic KRAS comparison; novel mode of EGFR ligand signaling\",\n      \"pmids\": [\"21514161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HIF-2α drives AREG expression through the endogenous AREG promoter via a non-canonical mechanism lacking a classical HIF-DNA interaction motif (HRE), establishing a novel mode of HIF-mediated gene regulation; HIF-2α-dependent AREG secretion activates EGF receptor family members in an autocrine loop promoting breast cancer cell self-sufficiency.\",\n      \"method\": \"HIF-2α knockdown/overexpression, ChIP assay on endogenous AREG promoter, EGFR family phosphorylation assays, patient tumor data correlation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP on endogenous promoter revealing novel mechanism, functional EGFR activation assays\",\n      \"pmids\": [\"21927022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AREG upregulates MMP-9 in metastatic breast cancer cells and promotes invasion through the MAPK/ERK pathway; MEK inhibition (PD98059) and MAPK antisense oligonucleotides significantly reduce AREG/EGF-induced MMP-9 secretion and invasion, placing AREG upstream of MAPK→MMP-9 in invasion signaling.\",\n      \"method\": \"MEK inhibitor PD98059, Ras inhibitor, PI3K inhibitor, MAPK antisense oligonucleotides, MMP-9 ELISA, invasion through Matrigel\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and antisense dissection of pathway; multiple inhibitors at different nodes\",\n      \"pmids\": [\"10389762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The CRTC1-MAML2 fusion oncogene upregulates AREG by co-activating the transcription factor CREB at the AREG promoter; secreted AREG then activates EGFR in an autocrine manner to promote mucoepidermoid carcinoma (MEC) cell growth and survival; CRTC1-MAML2-positive MEC cells are highly sensitive to EGFR inhibition.\",\n      \"method\": \"RNA interference of CRTC1-MAML2 and AREG, CREB co-activation reporter assay, EGFR inhibitor treatment, xenograft mouse models, gene expression analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown of oncogene and AREG with functional readouts in vitro and in vivo; CREB-mediated transcriptional mechanism defined\",\n      \"pmids\": [\"23975434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RASSF1A tumor suppressor activates the Hippo pathway (via MST kinases) to suppress YAP oncogenic activity, resulting in reduced AREG secretion from hepatocellular carcinoma cells; RASSF1A overexpression inhibits HCC cell proliferation and apoptosis induction via this RASSF1A→Hippo→YAP→AREG axis.\",\n      \"method\": \"RASSF1A overexpression in HCC cells, AREG secretion measurement (ELISA), apoptosis assays, proliferation assays, immunohistochemistry of human specimens\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with mechanistic pathway placement; confirmed in clinical specimens\",\n      \"pmids\": [\"23594797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-34c-5p directly targets the AREG 3'UTR (confirmed by luciferase reporter and mutant analysis) and suppresses AREG expression; AREG promotes ovarian cancer stemness (sphere formation, self-renewal) and drug resistance via the AREG→EGFR→ERK pathway, which is inhibited by miR-34c-5p.\",\n      \"method\": \"Luciferase reporter assay with wild-type and mutant AREG 3'UTR, miR-34c-5p overexpression, AREG overexpression, sphere formation assays, drug resistance assays, ERK pathway analysis\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct 3'UTR targeting confirmed by mutagenesis; functional pathway validated through multiple cell-based assays\",\n      \"pmids\": [\"28459431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Senescent stromal cells secrete AREG as a SASP (senescence-associated secretory phenotype) component in response to DNA damage; paracrine AREG activates EGFR on cancer cells to mediate acquired chemoresistance; senescent stromal AREG also induces PD-L1 expression in recipient cancer cells, creating immunosuppression; targeting AREG restores chemosensitivity and immunocompetency in humanized animal models.\",\n      \"method\": \"DNA damage-induced senescence models, AREG neutralization, EGFR inhibition, PD-L1 measurement, drug resistance assays, humanized animal xenograft models\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — paracrine mechanism defined with multiple functional readouts; in vivo validation in humanized animals\",\n      \"pmids\": [\"31493351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Multiple myeloma-derived exosomes are enriched in AREG; exosomal AREG activates EGFR in osteoclast precursors, inducing SNAIL mRNA expression; AREG-enriched exosomes promote osteoclast differentiation and block osteoblast differentiation in mesenchymal stromal cells, and stimulate IL-8 release from MSCs to drive osteoclastogenesis indirectly; anti-AREG neutralizing antibody reverses these effects.\",\n      \"method\": \"Exosome isolation from MM cell lines and patient BM plasma, EGFR activation assays, SNAIL qPCR, anti-AREG neutralizing antibody, OC differentiation assays (RAW264.7 and CD14+ primary cells), MSC co-culture, IL-8 ELISA\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection using primary human cells, patient samples, and antibody neutralization with multiple functional readouts\",\n      \"pmids\": [\"30621731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AREG expression in granulosa cells is elevated in OHSS patients; exogenous AREG treatment of granulosa cells stimulates VEGF expression and secretion via EGFR/HER2 signaling; siRNA-mediated knockdown of EGFR or AREG attenuates hCG-induced VEGF upregulation, establishing an AREG→EGFR/HER2→VEGF pathway in OHSS pathology.\",\n      \"method\": \"RT-qPCR of patient granulosa cells, AREG treatment of cultured granulosa cells, siRNA knockdown of EGFR and AREG, VEGF secretion assays\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient-derived cells with siRNA mechanistic validation; AREG→VEGF pathway defined\",\n      \"pmids\": [\"31167229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AREG mediates epithelial-mesenchymal transition (EMT) in pancreatic cancer via the EGFR→ERK→NF-κB signaling pathway; AREG stimulation increases NF-κB nuclear accumulation; NF-κB inhibitor blocks AREG-induced EMT, migration, and invasion; AREG silencing reduces tumor growth and metastasis in an orthotopic pancreatic cancer model.\",\n      \"method\": \"siRNA knockdown, exogenous AREG stimulation, wound-healing and Transwell invasion assays, Western blot for EMT markers and pathway components, NF-κB inhibitor, immunofluorescence, orthotopic xenograft model\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss- and gain-of-function with inhibitor pathway dissection; in vivo orthotopic model validation\",\n      \"pmids\": [\"32323797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AREG deficiency in mice essentially prevents bleomycin-induced skin fibrosis; bleomycin-induced dermal cell proliferation is absent in Areg-null mice; inhibiting MEK (a downstream effector of AREG-EGFR signaling) with selumetinib effectively blocks skin fibrosis, defining the Areg→EGFR→MEK signaling axis as critical for fibrosis development.\",\n      \"method\": \"Areg knockout mice, bleomycin-induced skin fibrosis model, histology, cell proliferation markers in dermis, MEK inhibitor (selumetinib) treatment, gene expression comparison between oral mucosa wound healing and skin fibrosis datasets\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knockout mouse model with defined phenotype (absence of fibrosis), pharmacological rescue experiment with MEK inhibitor\",\n      \"pmids\": [\"33622407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IL-17A promotes keratinocyte proliferation in psoriasis by stimulating recruitment of MST1 to the adaptor ACT1, which reduces MST1-LATS1 interaction, leading to YAP dephosphorylation and nuclear accumulation, which then activates AREG transcription; blocking YAP or IL-17A (secukinumab) suppresses the YAP-AREG axis in psoriatic skin.\",\n      \"method\": \"IL-17A stimulation of HaCaT and NHEK cells, ACT1 co-immunoprecipitation with MST1, YAP phosphorylation assays, AREG expression measurement, imiquimod mouse model, secukinumab treatment in patients\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP defines ACT1-MST1 interaction; mechanistic pathway confirmed in vitro and in vivo; clinical specimen validation\",\n      \"pmids\": [\"35304250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Mitochondrial dysfunction (loss of mitochondrial transcription factor A, TFAM) dramatically induces AREG expression as a hallmark retrograde signaling response; mitochondrial stress activates enhancers at the AREG locus through c-JUN/YAP1/TEAD axis; BRG1 chromatin remodeler represses these enhancers under normal conditions; this stress-responsive AREG induction is observed in murine liver injury models.\",\n      \"method\": \"TFAM knockout cells, transcriptomic analysis, ChIP-seq and ATAC-seq (epigenomic), c-JUN/YAP1 co-immunoprecipitation, motif enrichment analysis, mitochondrial stressor treatments, murine liver injury model\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multi-omic epigenomic approach with co-IP; genetic and chemical mitochondrial stress models; in vivo liver injury confirmation\",\n      \"pmids\": [\"36095121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GPR174 negatively regulates AREG expression in regulatory T cells (Tregs) by activating the Gαs/cAMP/PKA signaling pathway, which inhibits nuclear accumulation of EGR1 (early growth response protein 1), a transcriptional activator of AREG; GPR174 deletion in Tregs upregulates AREG, thereby enhancing endothelial cell function and reducing pro-inflammatory macrophage polarization to promote post-ischemic angiogenesis.\",\n      \"method\": \"Treg-specific GPR174 knockout mice, hindlimb ischemia model, EGR1 nuclear localization assay, cAMP/PKA pathway inhibitors, AREG expression measurement, endothelial cell functional assays, macrophage polarization assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific knockout with defined molecular mechanism (GPR174→Gαs→cAMP→PKA→EGR1→AREG); in vivo angiogenesis phenotype\",\n      \"pmids\": [\"36473866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"METTL3 methyltransferase induces m6A modification on AREG mRNA, stabilizing it and increasing AREG protein levels in pancreatic cancer; miR-33a-3p targets and suppresses METTL3, thereby reducing m6A-stabilization of AREG mRNA and inhibiting pancreatic cancer proliferation, migration, and invasion.\",\n      \"method\": \"RNA bisulfite sequencing (m6A mapping on AREG mRNA), METTL3 knockdown/overexpression, miR-33a-3p mimic/inhibitor, mRNA stability assays, rescue experiments, migration/invasion assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct m6A modification site mapping on AREG mRNA; mechanistic rescue experiments; multiple orthogonal functional assays\",\n      \"pmids\": [\"37604948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Small molecule inhibitors targeting the COX/AREG/EGFR/ERK autocrine loop (including COX inhibitors, EGFR inhibitors, and MEK/ERK inhibitors) attenuate CMV-induced salivary gland dysplasia, and ERK phosphorylation is required for initial mCMV-induced pathogenesis; this positions AREG as a critical node in CMV-triggered proliferative signaling.\",\n      \"method\": \"Mouse postnatal salivary gland organ culture model of mCMV infection, pathway-specific small molecule inhibitors (COX inhibitors, EGFR inhibitors, ERK inhibitors), ERK phosphorylation assays\",\n      \"journal\": \"Experimental and molecular pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of the AREG-containing pathway; organ culture model with defined pathological readout\",\n      \"pmids\": [\"21565184\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AREG (Amphiregulin) is an EGF family member synthesized as a 252-amino-acid transmembrane precursor that undergoes ectodomain shedding primarily by TACE/ADAM17 to release soluble AREG, which binds EGFR (ErbB1) to activate downstream MAPK/ERK, PI3K/Akt, and NF-κB signaling cascades governing cell survival, proliferation, migration, and EMT; AREG transcription is regulated by multiple upstream inputs including WT1, WNT/β-catenin, HIF-2α, YAP (downstream of the Hippo pathway via LATS1/2), IL-17A→ACT1→MST1→YAP, CRTC1-MAML2/CREB oncofusion, mitochondrial stress via c-JUN/YAP1/TEAD enhancer activation, and GPR174→Gαs/cAMP/PKA→EGR1 in Tregs; AREG can also signal in juxtacrine mode via its membrane-anchored precursor and is packaged into exosomes for paracrine delivery; physiologically, AREG is essential for liver regeneration, keratinocyte-mediated wound healing, and oocyte maturation, while pathologically it drives psoriasis, skin fibrosis (via EGFR→MEK), cancer stemness and chemoresistance (via EGFR→ERK), osteoclastogenesis in myeloma (via exosomal delivery), and immunosuppression through induction of PD-L1 in the tumor microenvironment; AREG mRNA stability is post-transcriptionally regulated by METTL3-mediated m6A modification, and miR-34c-5p directly targets the AREG 3'UTR to suppress its expression.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"AREG (amphiregulin) is a secreted EGF-family ligand that functions as a key autocrine and paracrine activator of EGFR signaling, coupling diverse upstream transcriptional inputs to mitogenic, pro-fibrotic, and immunomodulatory cellular responses. AREG binds and activates EGFR tyrosine kinase, driving downstream ERK and NF-κB cascades that promote epithelial-mesenchymal transition, cancer cell stemness, chemoresistance, osteoclast differentiation, and tissue fibrosis [PMID:1333777, PMID:32323797, PMID:30621731, PMID:33622407]. Its transcription is regulated by multiple context-dependent pathways including HIF-2α at the endogenous promoter, YAP/TEAD downstream of Hippo signaling (activated by IL-17A/ACT1 or mitochondrial stress), CRTC1-MAML2/CREB in mucoepidermoid carcinoma, and EGR1 in regulatory T cells, while its mRNA is post-transcriptionally stabilized by METTL3-mediated m6A modification [PMID:21927022, PMID:35304250, PMID:36095121, PMID:23975434, PMID:36473866, PMID:37604948]. Paracrine AREG from senescent stromal cells or tumor-derived exosomes promotes PD-L1 upregulation and immunosuppression, and genetic ablation of Areg in mice prevents bleomycin-induced skin fibrosis, establishing AREG as essential for pathological fibrotic remodeling [PMID:31493351, PMID:33622407].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing AREG as a functional EGFR ligand resolved its identity as an EGF-family growth factor rather than an uncharacterized mitogen.\",\n      \"evidence\": \"Protein purification with N-terminal sequencing and direct EGFR tyrosine phosphorylation assay\",\n      \"pmids\": [\"1333777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding affinity relative to other EGF-family members not determined\", \"Whether AREG activates other ErbB family members was not tested\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Chromosomal mapping of Areg to mouse chromosome 5 (linked with Btc) and identification of Sdgf as a species variant clarified the genomic context and resolved gene nomenclature confusion.\",\n      \"evidence\": \"Mouse chromosomal mapping and genomic linkage analysis\",\n      \"pmids\": [\"7590736\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional characterization of the genomic locus\", \"Regulatory elements at the locus not defined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying HIF-2α as a direct transcriptional activator of AREG via a non-canonical mechanism revealed how hypoxic tumor environments upregulate this autocrine EGFR ligand.\",\n      \"evidence\": \"ChIP at endogenous AREG promoter combined with HIF-2α siRNA and EGFR family phosphorylation readouts in breast cancer cells\",\n      \"pmids\": [\"21927022\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The non-canonical mechanism of HIF-2α recruitment to the AREG promoter was not structurally resolved\", \"Whether HIF-1α also regulates AREG was not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that the CRTC1-MAML2 fusion oncoprotein drives AREG transcription via CREB co-activation, feeding an autocrine EGFR loop in mucoepidermoid carcinoma, established a disease-specific transcriptional mechanism for AREG upregulation.\",\n      \"evidence\": \"RNAi of CRTC1-MAML2 and pharmacological EGFR inhibition with xenograft validation\",\n      \"pmids\": [\"23975434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CREB directly binds the AREG promoter was not shown by ChIP\", \"Contribution of other CREB target genes to MEC growth not dissected\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Placing AREG downstream of the Hippo pathway effector YAP (suppressed by RASSF1A/MST) linked a major tumor suppressor cascade to AREG secretion in hepatocellular carcinoma.\",\n      \"evidence\": \"RASSF1A overexpression with Hippo pathway activation assays and AREG secretion ELISA in HCC cells\",\n      \"pmids\": [\"23594797\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct YAP/TEAD binding at the AREG locus not shown in this study\", \"Single lab observation without independent replication\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Validating miR-34c-5p as a direct post-transcriptional repressor of AREG via its 3′UTR established a microRNA-based regulatory layer controlling the AREG-EGFR-ERK axis in cancer stemness and drug resistance.\",\n      \"evidence\": \"Luciferase reporter with mutant 3′UTR, sphere formation assays, and in vivo tumorigenicity in ovarian cancer models\",\n      \"pmids\": [\"28459431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other miRNAs cooperate with miR-34c-5p on the AREG 3′UTR was not explored\", \"Endogenous miR-34c-5p occupancy at AREG mRNA not shown by CLIP\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showing that senescent stromal cell-derived AREG confers chemoresistance and induces PD-L1 on cancer cells revealed AREG as a paracrine immunosuppressive factor in the tumor microenvironment.\",\n      \"evidence\": \"SASP factor neutralization, siRNA, flow cytometry for PD-L1, and humanized animal models\",\n      \"pmids\": [\"31493351\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The signaling pathway from EGFR to PD-L1 transcription was not fully delineated\", \"Whether anti-AREG therapy synergizes with checkpoint inhibitors in patients is unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying AREG as an upstream EGFR/HER2-dependent regulator of VEGF in granulosa cells connected AREG to vascular permeability in ovarian hyperstimulation syndrome.\",\n      \"evidence\": \"siRNA knockdown of AREG and EGFR plus exogenous AREG treatment with VEGF ELISA readout in cultured granulosa cells\",\n      \"pmids\": [\"31167229\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vivo validation of AREG-VEGF axis in OHSS\", \"Whether AREG is sufficient to induce OHSS phenotype not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that myeloma-derived exosomal AREG activates EGFR/SNAIL in osteoclast precursors to drive osteoclastogenesis expanded AREG's paracrine roles to bone remodeling in cancer.\",\n      \"evidence\": \"Exosome isolation from myeloma cells, anti-AREG neutralizing antibody blocking osteoclast differentiation of RAW264.7 and primary CD14+ cells\",\n      \"pmids\": [\"30621731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether exosomal AREG is the dominant osteoclastogenic factor in vivo not established\", \"Contribution of other exosomal cargo not controlled for\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Delineating the AREG→EGFR→ERK→NF-κB cascade as the mechanism for EMT induction in pancreatic cancer provided a stepwise signaling map downstream of AREG.\",\n      \"evidence\": \"Gain/loss-of-function, NF-κB pharmacological inhibition, and orthotopic mouse model in pancreatic cancer cells\",\n      \"pmids\": [\"32323797\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NF-κB-driven EMT markers are direct transcriptional targets was not confirmed by ChIP\", \"Relative contribution of AREG versus other EGFR ligands in pancreatic cancer not determined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Genetic ablation of Areg in mice essentially prevented bleomycin-induced skin fibrosis, establishing AREG as a non-redundant mediator of pathological fibrosis through the EGFR-MEK axis.\",\n      \"evidence\": \"Areg knockout mice with bleomycin fibrosis model and pharmacological MEK inhibition (selumetinib)\",\n      \"pmids\": [\"33622407\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AREG is required for fibrosis in other organs (lung, liver) not tested in this study\", \"The cellular source of AREG in fibrotic skin not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mapping the IL-17A→ACT1→MST1→YAP→AREG axis in keratinocytes revealed how inflammatory cytokine signaling co-opts Hippo pathway deactivation to drive AREG-dependent proliferation in psoriasis.\",\n      \"evidence\": \"Co-immunoprecipitation of ACT1-MST1, phosphorylation analysis, siRNA epistasis, and imiquimod/IL-17A mouse model\",\n      \"pmids\": [\"35304250\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether YAP directly binds AREG enhancers in keratinocytes was not shown by ChIP\", \"Contribution of other YAP targets to psoriatic phenotype not dissected\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ChIP-seq identification of c-JUN/YAP1/TEAD-bound enhancers at the AREG locus upon mitochondrial dysfunction (TFAM loss) established epigenomic remodeling as a mechanism for stress-induced AREG upregulation, with BRG1 serving as a default repressor.\",\n      \"evidence\": \"ChIP-seq, enhancer reporter assays, and transcriptomic analysis in hepatic cells with TFAM knockout\",\n      \"pmids\": [\"36095121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BRG1-mediated repression is direct or through chromatin remodeling intermediaries not resolved\", \"Functional contribution of individual enhancer elements not tested by deletion\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defining GPR174 as a negative regulator of AREG in Tregs via Gαs/cAMP/PKA-mediated cytoplasmic retention of EGR1 revealed a receptor-level mechanism controlling AREG's tissue-protective function in ischemia.\",\n      \"evidence\": \"Conditional GPR174 knockout mice, hindlimb ischemia model, pathway inhibitor studies, and EGR1 nuclear localization assays\",\n      \"pmids\": [\"36473866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether EGR1 directly binds the AREG promoter in Tregs was not confirmed by ChIP\", \"AREG-independent functions of Treg GPR174 not excluded\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identifying METTL3-mediated m6A modification as a stabilizer of AREG mRNA, counteracted by miR-33a-3p-dependent METTL3 suppression, added an epitranscriptomic regulatory layer to AREG expression in pancreatic cancer.\",\n      \"evidence\": \"RNA bisulfite sequencing, RIP-qPCR, EMSA, miRNA luciferase reporter, and METTL3 knockdown\",\n      \"pmids\": [\"37604948\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The specific m6A reader protein mediating AREG mRNA stabilization not identified\", \"In vivo relevance of METTL3-AREG axis not validated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for AREG's lower-affinity EGFR engagement compared to EGF, the identity of the m6A reader stabilizing AREG mRNA, whether AREG is essential for fibrosis in organs beyond skin, and the therapeutic window for anti-AREG strategies in cancer and fibrosis.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of the AREG-EGFR interface\", \"Reader protein for m6A-stabilized AREG mRNA unknown\", \"In vivo AREG requirement in lung/liver fibrosis not genetically tested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [13, 0, 1, 5, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [5, 0, 13]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 1, 3, 6, 7, 9, 10]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 6, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 10]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"EGFR\", \"YAP1\", \"METTL3\", \"EGR1\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Amphiregulin (AREG) is an EGF-family ligand synthesized as a 252-amino-acid transmembrane precursor that undergoes ADAM17/TACE-mediated ectodomain shedding to release a soluble heparin-binding growth factor that signals exclusively through EGFR (ErbB1), activating MAPK/ERK, PI3K/Akt, and NF-κB cascades to drive cell proliferation, survival, migration, and epithelial-mesenchymal transition [PMID:2466334, PMID:12743035, PMID:32323797]. AREG transcription is controlled by diverse upstream inputs including WT1, YAP/TEAD (downstream of Hippo/LATS1/2), HIF-2α, CRTC1-MAML2/CREB, IL-17A→ACT1→MST1→YAP, mitochondrial stress via c-JUN/YAP1, and GPR174→Gαs/cAMP/PKA→EGR1 in regulatory T cells, while AREG mRNA stability is post-transcriptionally regulated by METTL3-mediated m6A modification and miR-34c-5p targeting of the 3′UTR [PMID:10490105, PMID:19935651, PMID:35304250, PMID:36095121, PMID:36473866, PMID:37604948, PMID:28459431]. Beyond classical autocrine/paracrine shedding, AREG is packaged into exosomes for intercellular delivery, driving osteoclastogenesis in myeloma bone disease and promoting invasiveness in recipient cancer cells [PMID:21514161, PMID:30621731]. Physiologically, AREG is essential for liver regeneration after partial hepatectomy and for dermal fibrosis downstream of EGFR→MEK signaling, and its overexpression in keratinocytes is sufficient to produce psoriasis-like skin pathology [PMID:15685553, PMID:33622407, PMID:9410906].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Identification of AREG as a novel bifunctional growth factor resolved the question of whether breast carcinoma cells secrete factors with both growth-inhibitory and growth-stimulatory activities depending on target cell type.\",\n      \"evidence\": \"Purification from PMA-treated MCF-7 conditioned medium with bioassays on carcinoma and fibroblast cells\",\n      \"pmids\": [\"3413110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor identity unknown\", \"Gene structure unknown\", \"Mechanism of bifunctional activity not defined\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Sequencing revealed AREG as an EGF-family member that binds EGFR, establishing its receptor specificity and positioning it within the broader EGF ligand family.\",\n      \"evidence\": \"Complete amino acid sequencing, EGF receptor competition binding assay, keratinocyte growth assay\",\n      \"pmids\": [\"2466334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding affinity quantification incomplete\", \"Signaling pathway downstream of EGFR not yet mapped\", \"No structure-function dissection of heparin-binding domain\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Cloning of the AREG gene revealed a 252-amino-acid transmembrane precursor architecture analogous to TGF-α, establishing that AREG is synthesized as a membrane-anchored protein requiring proteolytic processing.\",\n      \"evidence\": \"Gene cloning, sequencing, chromosomal mapping to 4q13–q21, Northern blot\",\n      \"pmids\": [\"2325643\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the processing protease unknown\", \"Whether juxtacrine signaling occurs from unprocessed precursor untested\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Systematic receptor pairing experiments demonstrated that AREG signals exclusively through EGFR (ErbB1) and does not directly activate ErbB-2, ErbB-3, or ErbB-4, distinguishing it from neuregulins and defining its receptor exclusivity.\",\n      \"evidence\": \"Ba/F3 cells expressing individual and pairwise ErbB receptors; tyrosine phosphorylation and survival assays\",\n      \"pmids\": [\"8702723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AREG induces EGFR heterodimerization with other ErbB members in endogenous contexts not addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Transgenic keratinocyte-specific AREG overexpression producing a psoriasis-like phenotype established that AREG gain-of-function is sufficient to drive inflammatory hyperproliferative skin disease in vivo.\",\n      \"evidence\": \"K14 promoter-driven AREG transgenic mice; histological analysis\",\n      \"pmids\": [\"9410906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endogenous AREG upregulation is necessary for human psoriasis not tested\", \"Downstream immune cell recruitment mechanism undefined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of WT1 as a direct transcriptional activator of the AREG promoter, coupled with AREG's ability to stimulate kidney epithelial branching, linked AREG to developmental morphogenesis downstream of a tumor suppressor.\",\n      \"evidence\": \"Inducible WT1 expression, EMSA/promoter binding, reporter assays, kidney organ culture with recombinant AREG\",\n      \"pmids\": [\"10490105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo requirement for AREG in kidney development not tested via knockout\", \"Other WT1 targets may contribute to branching\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"ADAM17/TACE was identified as the specific sheddase for AREG, and GPCR-induced EGFR transactivation was shown to require TACE-mediated AREG release, solving the long-standing question of how GPCRs activate EGFR.\",\n      \"evidence\": \"siRNA of AREG and TACE, dominant-negative TACE, TIMP-3 inhibitor, neutralizing antibodies; LPA/carbachol stimulation\",\n      \"pmids\": [\"12743035\", \"12711607\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other ADAMs contribute under specific conditions not excluded\", \"Structural basis for TACE recognition of AREG cleavage site unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"AREG-null mice revealed an essential, non-redundant role for AREG in hepatocyte proliferation during liver regeneration, induced by IL-1β/PGE2 rather than HGF or IL-6.\",\n      \"evidence\": \"Areg knockout mice, partial hepatectomy, primary hepatocyte proliferation assays, cytokine stimulation\",\n      \"pmids\": [\"15685553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compensatory upregulation of other EGFR ligands at later time points not fully characterized\", \"Mechanism of IL-1β/PGE2 induction of AREG transcription not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstration that membrane-anchored AREG activates EGFR in adjacent cells via juxtacrine signaling, in addition to autocrine shedding-dependent signaling, established a dual-mode signaling capability.\",\n      \"evidence\": \"Juxtacrine overlay assay, metalloprotease inhibitor GM6001, EGFR inhibitors, invasion/motility assays in SUM149 breast cancer cells\",\n      \"pmids\": [\"17035230\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative physiological importance of juxtacrine vs. autocrine signaling in tissues unknown\", \"Structural basis for juxtacrine EGFR activation not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"YAP was established as a transcriptional inducer of AREG downstream of Hippo pathway suppression, and AREG secretion was shown to mediate YAP's non-cell-autonomous proliferative effects, linking the Hippo pathway to EGFR ligand production.\",\n      \"evidence\": \"YAP overexpression, AREG knockdown, EGFR inhibitor, co-culture paracrine assay, LATS1/2 siRNA, Drosophila yorkie/EGFR epistasis\",\n      \"pmids\": [\"19935651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether YAP binds the AREG promoter directly or through TEAD cofactors not resolved at this point\", \"Relative contribution of AREG vs. other YAP targets to organ size control unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovery that cancer-cell-derived exosomes carry signaling-competent AREG that is more potent than soluble AREG in promoting invasiveness revealed an unconventional paracrine delivery mechanism for EGFR ligands.\",\n      \"evidence\": \"Exosome isolation, quantitative mass spectrometry (~24 AREG/exosome), invasion assays, KRAS isogenic cell lines\",\n      \"pmids\": [\"21514161\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of AREG sorting into exosomes unknown\", \"Whether exosomal AREG is cleaved or full-length transmembrane form not fully resolved\", \"In vivo exosomal AREG bioavailability not quantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"miR-34c-5p was shown to directly target the AREG 3′UTR, and AREG→EGFR→ERK signaling was demonstrated to promote cancer stemness and chemoresistance, establishing post-transcriptional control and a functional link to tumor-initiating cell properties.\",\n      \"evidence\": \"Luciferase reporter with wild-type/mutant AREG 3′UTR, sphere formation, drug resistance assays, ERK pathway analysis in ovarian cancer\",\n      \"pmids\": [\"28459431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Broader miRNA regulatory landscape of AREG not mapped\", \"In vivo relevance of miR-34c-5p→AREG axis in chemoresistance untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Senescent stromal cells were found to secrete AREG as a SASP component that confers chemoresistance and induces PD-L1 on cancer cells, establishing AREG as a mediator of the immunosuppressive tumor microenvironment.\",\n      \"evidence\": \"DNA damage-induced senescence, AREG neutralization, PD-L1 measurement, humanized animal xenograft models\",\n      \"pmids\": [\"31493351\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AREG-induced PD-L1 operates via NF-κB or another pathway not defined\", \"Clinical relevance of anti-AREG immunosensitization not tested in patients\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Exosomal AREG from myeloma cells was shown to activate EGFR in osteoclast precursors and suppress osteoblast differentiation, defining a mechanism for myeloma bone disease mediated by AREG-containing exosomes.\",\n      \"evidence\": \"Exosome isolation from MM cell lines and patient bone marrow, anti-AREG neutralizing antibody, osteoclast differentiation assays, MSC co-culture\",\n      \"pmids\": [\"30621731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo bone lesion formation studies with AREG blockade not performed\", \"Whether other exosomal cargo synergizes with AREG not investigated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"AREG-null mice were completely protected from bleomycin-induced skin fibrosis, and MEK inhibition phenocopied this protection, defining the AREG→EGFR→MEK axis as essential for dermal fibrotic responses.\",\n      \"evidence\": \"Areg knockout mice, bleomycin fibrosis model, selumetinib (MEK inhibitor), histology and proliferation markers\",\n      \"pmids\": [\"33622407\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AREG drives fibrosis in other organs (lung, kidney) via the same mechanism untested\", \"Cell source of AREG in fibrotic dermis not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Multiple studies converged on the transcriptional regulation of AREG: IL-17A→ACT1→MST1→YAP in psoriatic keratinocytes, mitochondrial stress→c-JUN/YAP1/TEAD enhancer activation, and GPR174→Gαs/cAMP/PKA repression of EGR1→AREG in Tregs, revealing context-specific regulatory inputs that funnel through distinct pathways onto the AREG locus.\",\n      \"evidence\": \"Co-IP of ACT1-MST1, YAP phosphorylation assays, imiquimod mouse model, TFAM knockout with ChIP-seq/ATAC-seq, Treg-specific GPR174 knockout with hindlimb ischemia model\",\n      \"pmids\": [\"35304250\", \"36095121\", \"36473866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each transcriptional input in different tissues not quantified\", \"Enhancer architecture at the AREG locus not fully characterized across cell types\", \"Whether c-JUN/YAP1 and IL-17A/YAP converge on the same enhancer elements not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"METTL3-mediated m6A modification of AREG mRNA was shown to stabilize the transcript and increase AREG protein output, adding an epitranscriptomic layer to AREG regulation.\",\n      \"evidence\": \"RNA bisulfite sequencing mapping m6A sites on AREG mRNA, METTL3 knockdown/overexpression, mRNA stability assays, rescue experiments in pancreatic cancer cells\",\n      \"pmids\": [\"37604948\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the m6A reader protein mediating AREG mRNA stabilization unknown\", \"Whether m6A regulation of AREG is tissue-specific not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for AREG's exclusive EGFR specificity and lower binding affinity compared to EGF, the mechanism by which AREG is selectively sorted into exosomes, whether AREG's juxtacrine versus autocrine/exosomal signaling modes have distinct physiological roles in vivo, and the identity of the m6A reader that stabilizes AREG mRNA.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of AREG-EGFR complex available\", \"Exosomal sorting mechanism of AREG uncharacterized\", \"Relative in vivo contributions of juxtacrine, autocrine, and exosomal AREG signaling undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 5, 7, 14]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 10, 14]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 11, 13, 17, 24]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [17, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 5, 7, 11, 16, 22, 26]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 22, 23, 26, 27]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [14, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [23, 30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"EGFR\",\n      \"ADAM17\",\n      \"YAP1\",\n      \"TEAD\",\n      \"WT1\",\n      \"METTL3\",\n      \"EGR1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}